Improved Efficacy of Localized Brain Tumor Therapy using Photosensitive Nanoparticles. by Simmer, Kristen Anastasia
Improved Efficacy of Localized Brain Tumor  




Kristen Anastasia Simmer 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Biophysics) 
















 Professor Raoul Kopelman, Chair 
 Assistant Professor Julie Suzanne Biteen 
 Professor Ari Gafni 
 Professor Martin A. Philbert 




















To my nieces and nephews, for your youthful spirit  
and innocent outlook of the world – I thank you.  
May each of you appreciate your potential  





































I would like to begin by thanking my mentor, Dr. Raoul Kopelman, for his guidance and expertise. 
From the start of my career he was always supportive of my ideas and has provided me the 
opportunity to explore new ideas of research both under his supervision and under the direction of 
collaborators. He provided a truly challenging and enlightening educational experience. 
Special thanks to Dr. Martin Philbert, whose vast expanse of knowledge has been a constant source 
of information. I have learned so much from him, especially after having him as an instructor of 
pathology. Now that I am finishing the program, I can look back at the immense value of his lecture 
style and one-on-one discussions. His guidance has changed my perspective on the biological and 
clinical relevance of science. 
I am very thankful to Dr. Ari Gafni for his mentorship at the start of my career. He set the standard 
as my first graduate lab mentor, and also gave me direction as the Biophysics graduate chair.I 
would like to express my deepest gratitude to the other distinguished members of my graduate 
committee, Dr. Julie Biteen and Dr. Michael Zochowski for their valuable critiques of my research. 
I would also like to thank my collaborators on these projects, Dr. Oren Sagher, Dr. Daniel Orringer, 
Dr. Martin Philbert, and Mr. Dah-Luen Huang. It was a pleasure to work with such an elite group 
of experts from whom I gained a rich clinical acumen. 
iv 
 
Thank you to Dr. Yong-Eun Lee Koo for always making time to review my experimental 
objectives and conclusions, as well as her excellent critique and guidance for future works. Her 
vast knowledge of cancer research was an inspiration for my graduate career and future endeavors. 
Thank you to the past members of the Kopelman group, who have contributed to my research as 
well as my graduate experience. To Dr. Hoe Sin Hah, Dr. Gwangseong Kim, Dr. Shouyan Wang, 
and Dr. Qinghong Yao for sharing their knowledge of nanoparticle synthesis and application. 
To my lab mates, Remy Elbez and Ariel Hecht for being such wonderful friends and helping to 
ease the stress of graduate life with an eclectic array of movie nights. A huge thank you to Dr. 
Aniruddha Ray for being one of my closest friends. I will forever remember the untraceable walks 
around Ann Arbor, and your enthusiasm while helping to celebrate my biggest achievements. Also 
thank you to the current members of the Kopelman group, Leshern Karamchand for his constant 
concern of my happiness; Hyung Ki Yoon, Teppei Shirakura, and Ming Qin for their hilarious 
banter and always lending a helping hand for nanoparticle synthesis. 
My deepest appreciation to Dr. Andrei Kogan, my professor and supervisor during my 
undergraduate career at the University of Cincinnati. He always had great enthusiasm in the 
classroom and extended our relationship personally by encouraging me to further my physics 
career. He instilled in me a curiosity in the experimental sciences and was instrumental in my 
pursuit of graduate studies. I would also like to thank Dr. Richard Gass and Dr. Cenalo Vaz for 
their early mentorship in my studies at the University of Cincinnati and initiating me into the 
pursuit of a degree in physics. A special thank you to the University of Cincinnati physics, graduate 




I would like to acknowledge the funding from the National Institute of Health, Rackham Travel 
Grant, and Rackham Merit Fellowship.  
I would like to thank all of my friends from all walks of life for their support and love throughout 
the years. Special gratitude to D.C., G.A., A.R., P.M., and A.V. for their uncompromising 
friendship and frequent words of advice. To the parish of the Greek Orthodox Church of Cincinnati 
for their constant praise and reassurance. 
Most important, I would like to dedicate my thesis to my loving family. Thank you to my parents, 
Dennis and Anastasia Herrmann, and to my siblings Melissa, AnnaMarie, and Nick and their 
families for their endless love, faith, and encouragement to pursue my educational dreams. To my 
grandparents, Betsy Pascal and Jean Herrmann-Heisler, who do not measure my success by my 
achievements but rather my happiness. To my husband’s family for their great generosity and 
willingness to always help me achieve my goals. And an exceptional thank you to my husband, 
Stephen Simmer, for always being by my side. I thank him for his constant encouragement and 
perpetual love. Finally to my puppy Jill, for her enthusiastic puppy kisses and continuously 



























  References………………………………………………………………………..14 
 
2. Delayed Brain Tumor Growth Using Methylene Blue Mediated Photodynamic 
Therapy…………………………………………………………………………………..19 
  Introduction………………………………………………………………………19 
Experimental……………………………………………………………………..23 
  Results and Discussion……………………………………………………….…..32 
  Conclusions………………………………………………………………………50 
  Acknowledgement……………………………………………………………….51 
  References………………………………………………………………………..51 
 
3. Evaluating the Effect of HPPH Mediated Photodynamic Therapy for Arresting Glioma.56 
  Introduction……………………………………………………………………....56 
  Experimental……………………………………………………………………..59 
  Results and Discussion……………………………………………………….…..68 
  Conclusions………………………………………………………………………86 
  Acknowledgement……………………………………………………………….87 
  References………………………………………………………………………..88 
 
4. Efficacy of Reactive Oxygen Species Production for Methylene Blue and Coomassie Blue 
Mixture: For Possible Combined Tumor Delineation and Therapy…………………..…..93 
Introduction………………………………………………………………………93 
  Experimental……………………………………………………………………..96 
  Results and Discussion…………………………………………………………...97 
  Conclusions……………………………………………………………………..102 
  Acknowledgement……………………………………………………………...103 




5. Future Directions………………………………………………………………………..106 























List of Figures 
 
Figure 1.1: Reaction kinetics of photosensitization leading to PDT……………………………...5 
Figure 2.1: Surface modification and conjugation of MB-loaded PAA nanoparticles………….25 
Figure 2.2: (A) Size distribution of polyacrylamide nanoparticles in solution using dynamic light 
scattering measurments. ROS production measurement of (B) Methylene Blue free dye in DI water 
and (C) Methylene Blue polyacrylamide nanoparticles. Peak excitation for Methylene Blue was 
found at 678 nm: linear fitted plot of fluorescence change in ADPA as a function of irradiation 
time………………………………………………………………………….…………………...34 
Figure 2.3: Examination of cytotoxicity using the MTT assay. Cell viability of 9L gliosarcoma, 
evaluated after 24 hours incubation with varying concentrations of F3-targeted and non-targeted 
Methylene Blue nanoparticles.  Cell survival rates indicated no measurable variance between 
nanoparticle concentrations (0.1, 0.2, 0.5, and 1.0 mg/mL), including the cell only control group 
(no NPs)……………………………………………………………………………………….....35 
Figure 2.4: Confocal images of 9L cell lines treated with Methylene Blue-conjugated PAA 
nanoparticles. Intensity dependent cytotoxicity, induced by F3-targted Methylene Blue PAA 
nanoparticles and laser irradiation. The 9L gliosarcoma cells were incubated with Methylene Blue 
nanoparticles and irradiated with fluencies of 100 mW/cm2 and 222 mW/cm2. Images were taken 
(a) before light exposure; (b-e) over 30 min of light exposure at a dose of 100 mW/cm2. Images 
were taken (f) before light exposure; (g-j) over 30 min light exposure at a dose of 222 mW/cm2. 
Cytotoxicity was monitored by labeling the cells with Calcein-AM (green, for viable cells) and 
propidium iodide (red, for dead cells). Measurements taken on a confocal 
microscope……………………………………………………………………………………….37 
Figure 2.5: Cell viability assessment for the phototoxic effects of F3-targeted Methylene Blue 
polyacrylamide nanoparticles on a 9L cell line. Fluency dependent PDT efficiency at light doses 
of 100 mW/cm2 and 222 mW/cm2, over the course of 30 minutes of illumination.  Cells exposed 
to a higher fluency responded with a more rapid cellular death than for a lower fluency……….38 
Figure 2.6: Confocal images of 9L cell lines treated with Methylene Blue-conjugated PAA 
nanoparticles, before and after laser illumination. Cell viability was monitored by labeling cells 
with Calcein-AM (green, viable cells) and propidium iodide (red, dead cells). Images were taken 
before illumination at 60X magnification. Post-illumination images were taken at a lower 




Figure 2.7: A series of cranial window pictures of a rat with an implanted 9L glioma, before and 
after the PDT, using F3-Methylene Blue polyacrylamide nanoparticles and a time interval of 
105min between nanoparticle injection and light illumination. The dotted circle encloses the tumor 
area in each picture………………………………………………………………………...……..42 
Figure 2.8: (A) Photograph displaying therapy setup. Rats with BTW are positioned in sterotactic 
frames with distance between cranial window and laser collimator fixed at 1 inch. Photographs of 
a tumor as seen through the BTW (B) before therapy and (C) during irradiation with a 671nm 
laser…………………………………………………………………………………………...….43 
Figure 2.9: Incubation time dependent effects of photodynamic therapy treatment. F3-targeted 
Methylene Blue polyacrylamide nanoparticles were intravenously injected, and once completing 
105 minutes or 24 hours of systemic incubation, the tumors were irradiated at 180 J/cm2 through 
the BTW and observed daily……………………………………………………………………..44 
Figure 2.10: Daily photographs of the cortical surface depict tumor growth, images taken through 
brain tumor windows on rat models. Animals groups receiving irradiation experienced a fluence 
dose of 180 J/cm2 using 671 nm laser……………………………………………….…………...45 
Figure 2.11: Effect of PDT treatment delivered 105 minutes after injection of Methylene Blue F3-
targeted nanoparticles, Methylene Blue PEGylated nanoparticles and Methylene Blue free dye. 
The control animal was not administered with photosensitizer or exposed to the laser illumination. 
Another control animal group treated with light illumination showed the same tumor growth trend 
as the “no treatment” control animal group……………………………………………………...47 
Figure 2.12: Post-PDT treatment necrotic tissue measurements for tumors treated with F3-targeted 
Methylene Blue polyacrylamide nanoparticles verses non-targeted (PEGylated) Methylene Blue 
nanoparticles. Both treatment groups express similar necrotic formation and regression patterns 
with a greater formation of necrotic tissue for non-targeted Methylene Blue 
nanoparticles……………………………………………………………………………………..48 
Figure 2.13: Gross specimen from animal model, excised 10 days post-PDT therapy. 
Representation of brain tumor for animal groups (A,B) without photosensitizer or laser 
illumination, and (C,D) animals receiving non-targeted Methylene Blue nanoparticles (105 minute 
incubation time) with irradiation fluence dose of 180 J/cm2 using a 671 nm laser……………...49 
Figure 3.1: Surface modification and conjugation of HPPH post-loaded PAA nanoparticles….61 
Figure 3.2: Cytotoxicity test using the MTT assay. Cell viability of 9L gliosarcoma, evaluated 
after 24 hours incubation, with varying concentrations of F3-targted and non-targeted HPPH 
polyacrylamide nanoparticles. Cell survival rates indicated no measurable differences among 
nanoparticle concentrations (0.1, 0.2, 0.5, and 1.0 mg/mL), including the cell only control group 
(not treated with nanoparticles)………………………………………………………………….70 
Figure 3.3: (A) Size distribution of polyacrylamide nanoparticles in solution as measured by DLS. 
(B) ROS production measurement of HPPH post-loaded polyacrylamide nanoparticles in DI water, 
x 
 
with excitation peak for HPPH at 665nm: Linear fitted plot of fluorescence change of ADPA as a 
function of irradiation time, irradiation performed at 378nm…………………………….……….71 
Figure 3.4: Confocal images of 9L cell lines treated with F3-targeted HPPH post-loaded PAA 
nanoparticles. Intensity dependent cytotoxicity, induced by F3-targted HPPH PAA nanoparticles 
and laser irradiation at 671 nm. The 9L gliosarcoma cells were incubated with HPPH nanoparticles 
and irradiated with fluencies of 100 J/cm2 and 144 J/cm2. Images were taken (A) before light 
exposure; (B-E) over 30 min of light exposure at a dose of 100 mW/cm2. Images were taken (F) 
before light exposure; (G-J) over 30 min light exposure at a dose of 144 mW/cm2. Cytotoxicity 
was monitored by labeling the cells with Calcein-AM (green, for viable cells) and propidium 
iodide (red, for dead cells). Measurements taken on a confocal microscope.………… ….........…72 
Figure 3.5: Cell viability assessment for the phototoxic effects of F3-targeted HPPH post-loaded 
polyacrylamide nanoparticles on a 9L cell line. Fluency dependent PDT efficiency at light doses 
of 100 mW/cm2 and 144 mW/cm2, over the course of 20 minutes of illumination.  Cells exposed 
to a higher fluency responded with a more rapid cellular death than for a lower fluency. ..........….73 
Figure 3.6: (A) Photograph displaying photodynamic therapy setup. Rats with BTW are placed in 
sterotactic frames with distance between cranial window and laser collimator fixed at 1 inch. 
Photographs of a tumor as seen through the BTW (B) before laser therapy and (C) during 
irradiation with a 671nm laser……………………………….…………………………………...74 
Figure 3.7: A series of cranial window pictures of an implanted 9L glioma, before and after the 
PDT, using non-targeted HPPH polyacrylamide nanoparticles and a time interval of 6 hours 
between nanoparticle injection and light illumination. The dotted circle encloses the tumor area in 
each picture…………………………..…………………..………………………………………75 
Figure 3.8: BTW view of the brain on the day of photodynamic therapy (Day 0), showing tumor 
growth of approximate size of 3mm. Days following PDT treatment, extensive necrosis was seen 
in the treatment area for those animals administered HPPH nanoparticles and irradiated with the 
laser light…………………………………………………………………………………………77 
Figure 3.9: Tumor response as a result of delivery dependent photodynamic therapy. HPPH in the 
form of free dye and post-loaded in nanoparticles, F3-targeted or non-targeted polyacrylamide 
nanoparticles, were intravenously injected. Following nanoparticle incubation time of 105 minutes 
tumors were irradiated at 180 J/cm2 using 671 nm laser light through the BTW and observed 
daily…………………………………………………………………….………………………...79 
Figure 3.10: Tumor necrosis measurements. Following nanoparticle incubation time of 105 
minutes tumors were irradiated at 180 J/cm2, for 30 minutes, using 671 nm laser light. 
Measurements were taken for animal groups treated with non-targeted HPPH PEGylated 
polyacrylamide nanoparticles and F3-targted HPPH polyacrylamide nanoparticles. Both treatment 
groups demonstrate irradiation induced tumor necrosis…………………….……………………79 
Figure 3.11: Tumor response for variations in incubation times of non-targeted HPPH PEGylated 
polyacrylamide nanoparticles. Following nanoparticle incubation time of 105 minutes, , 6 hours, 
xi 
 
and 10 hours tumors were irradiated at 180 J/cm2 using 671 nm laser light through the BTW and 
observed daily……………………………………………………………………………………81 
Figure 3.12: Tumor necrosis measurements for variations in incubation times of non-targeted 
HPPH PEGylated polyacrylamide nanoparticles. Following nanoparticle incubation time of 105 
minutes, 6 hours, and 10 hours tumors were irradiated at 180 J/cm2 using 671 nm laser light. 
Prolonged duration of tumor necrosis found in treatment groups receiving irradiation following 6 
hour incubation…………………………………………………………………………………..81 
Figure 3.13: Representation of animal groups receiving PEGylated HPPH polyacrylamide 
nanoparticles with systemic incubation time of 6 hours between nanoparticle administration and 
laser illumination. Photographs depict the brain as seen through the BTW on the day of 
photodynamic therapy (Day 0), showing tumor growth of approximate size of 3mm, and the days 
post-treatment. Days following PDT treatment, significant necrosis was seen in the treatment area 
for all animal groups following PDT treatment………………………………………………….82 
Figure 3.14: Response of glioma treated with HPPH post-loaded PEGylated polyacrylamide 
sensitized at 671 nm using varying irradiation regimens. Following nanoparticle incubation time 
of 6 hours tumors were irradiated at 180 J/cm2 (100 mW/cm2) – 30 minute illumination, 260 J/cm2 
(100 W/cm2) – 45 minute illumination, and 260 J/cm2 (144 mW/cm2) – 30 minute 
illumination…………………………………………..…………………………………………..84 
Figure 3.15: Tumor necrosis measurements for variations in fluence rates of exposed non-targeted 
HPPH PEGylated polyacrylamide nanoparticles. Following nanoparticle incubation time of 6 
hours tumors were irradiated at 180 J/cm2 (100 mW/cm2) – 30 minute illumination, 260 J/cm2 (100 
W/cm2) – 45 minute illumination, and 260 J/cm2 (144 mW/cm2) – 30 minute illumination, using 
671 nm laser light. Tumor necrosis as seen through the BTW, observed 
daily………………………………………………………………………………………………84 
Figure 3.16: Gross specimen from animal model, excised 10 days post-PDT therapy. 
Representation of brain tumor for animal groups (A,B) without photosensitizer or laser 
illumination, and (C,D) animals receiving non-targeted HPPH nanoparticles (6 hour incubation 
time) with irradiation fluence dose of 260 J/cm2 (144 mW/cm2) using a 671 nm laser…………85 
Figure 4.1: Fluorescence spectra of ADPA over time course of 30 minutes……………………98 
Figure 4.2:   ADPA was used to detect the ROS production from Methylene Blue when combined 
with Coomassie Blue dye. The logarithm of the ratio of ADPA fluorescence intensity at 431nm 
provides the first order decay rate constant, or k-value. A) Calculation of the rate of ROS 
production from MB free dye using ADPA. (B-J) ROS production of various MB:CB 
mixtures…………………………………………………………………………………………..99 
Figure 4.3: Comparison of ROS generation from the various compositions of Methylene Blue and 








Currently, surgical resection serves as the leading management for the treatment of brain tumors. 
Performing a maximal resection must be balanced with the need to preserve adjacent non-
cancerous brain tissue, and even with the best microsurgical technique, resection may leave behind 
residual tumor tissue. In order to provide a better approach to treat cancer patients, a minimally 
invasive localized treatment, photodynamic therapy (PDT), has been utilized to specifically treat 
localized and superficial tumors. PDT uses exogenously administered photosensitizers, such as 
Methylene Blue and HPPH, which are activated by a specific wavelength of light. The sensitizer, 
in its excited state, transfers its energy to molecular oxygen, forming reactive oxygen species 
which irreversibly oxidize essential cellular components, resulting in injury and necrosis of nearby 
tumor tissue. 
Photosensitizer-conjugated polyacrylamide nanoparticles were prepared for in vivo 
characterization of the minimally invasive and localized treatment of photodynamic therapy on 
brain tumors. PDT efficiency was improved by incorporating a variety of nanoparticle matrixes, 
photosensitizers, and targeting methods as well as exploring the systemic incubation of 
nanoparticles and fluence dependence on tumor response. Advancements and considerable 
attention to nanoparticle characteristics, incubation time, and photosensitizer delivery are proving 
allowance for further PDT quantification. Tumor growth patterns and tumorigenic response to 
various treatments were determined via visual observation by the use of an animal cranial window 
model. PDT treatments with photosensitizer loaded polyacrylamide nanoparticles, both with F3-
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targeting and PEG, displayed worthy homing and passive targeting efficiency towards the 
implanted 9L glioma, as shown by the significant phototoxic effect, killing the tumor cells in the 
treatment area of the cranial window. These photoreactive nanoparticles produced significant 
adjournment of tumor growth over control groups, clearly demonstrating the advantages of 
nanoparticle-based PDT agents. The advancements in therapy efficacy described in this thesis, has 
the potential to be utilized as an aid to neurosurgery for the eradication of local tumors, leading to 
the potential palliation of the advancing disease. This form of treatment can be extended to many 








Cancer is one of the most common causes of death in the US, only second to heart disease, 
accounting for nearly a half a million deaths each year. The National Cancer Institute approximated 
in 2012 that 13.7 million people in the United States have either survived or have evidence of 
cancer and may be undergoing treatment [1]. 
Glioma 
Approximately 13,700 deaths and 24,600 new cases of primary malignant brain and central 
nervous system (CNS) tumors occur annually in the US [2]. Of the various types of cancer, primary 
tumors of the CNS account for 2% of human malignancies, with malignant glioma being the most 
common CNS cancer in adults. In general, malignant gliomas are not curable tumors, making it 
one of the deadliest forms of cancer. Patients diagnosed have a mean survival of a little over a 
year, and only 20 weeks for those with recurring brain cancer [3-5]. 
Primary brain (intracerebral) tumors, also referred to as gliomas, encompass all tumors that are 
thought to be of glial cell origin. Comprising 50-60% of all adult brain tumors, gliomas include 
astrocytic tumors, oligodendrogliomas, ependymomas, and mixed gliomas [2,6]. The World 
Health Organization (WHO) divides gliomas into four grades, based on differentiation and 
histopathologic characteristics of the tumor, with glioblastoma being classified as the highest grade 
tumor (grade IV) [6]. 
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Glioma therapy & treatment 
Treatment of tumors of glial origin, gliomas, remains challenging due to considerable molecular 
and cellular heterogeneity. Numerous treatment modalities have been applied, surgical 
resectioning, radiation, and chemotherapy, and have helped improve the quality of life and survival 
for patients [7]. Surgical resection serves as the leading mode of management for the treatment of 
brain tumors. Mounting evidence suggests that maximal surgical resection correlates with an 
improvement in survival in patients with glioma [7-8]. Performing a maximal resection must be 
balanced with the need to preserve adjacent non-cancerous brain tissue. Even with the best 
microsurgical technique, resection may leave behind residual tumor tissue. In order to provide a 
better approach to treat cancer patients, an adjuvant therapy, secondary to surgery, may be applied, 
in attempt to kill any remaining tumor cells. Radiation therapy and chemotherapy can be the means 
of treatment to combat residual tumor cells post-surgery. 
Radiotherapy employs high-energy ionizing radiation to kill cells by directly damaging their DNA, 
or by the creation of free radicals within cells that will ultimately damage the cell’s DNA [1]. 
Although this additional treatment may be essential for potential palliation of the tumor, the 
therapy is not localized and can damage healthy cells, as well as the cancer cells, leading to partial 
loss of brain function, causing memory loss, personality inconsistency, and difficulty 
concentrating [1]. 
Another treatment method readily used in addition to surgical resectioning of tumors, is 
chemotherapy. Chemo drugs can be administered to the patient intravenously or taken orally. Some 
of these drugs include, but are not limited to: cisplatin, carboplatin, etoposide, paclitaxel, and 
temozolomide (TMZ) [9]. The most widely used chemo treatment method for patients with 
glioblastoma utilizes the orally administered temozolomide [10]. However this alkylating drug can 
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lead to systemic toxicity and long-term side effects, associated with most conventionally used 
chemotherapy drugs: hair loss, lethargy, increased susceptibility to infection, fatigue, etc. [1]. In 
addition, glioblastoma can develop multi-drug resistant (MDR) proteins, limiting the delivery, and 
thus, the effectiveness of chemotherapy drugs [11]. This inability of chemo drugs to be delivered 
with a full payload could cause further tumor growth and a high frequency of tumor recurrence 
post-therapy. 
The major challenge associated with brain tumor therapies is the preferential destruction of 
malignant tissue while sparing eloquent tissue. Although surgical resection remains to be the 
primary method of treatment, gliomas are well known for diffusely infiltrating adjacent cerebral 
parenchyma, making clear tumor margins differentiation difficult [12]. A minimally invasive and 
localized treatment, photodynamic therapy (PDT), has been utilized to specifically treat superficial 
tumors reaming after surgical resectioning [13-15]. PDT uses exogenously administered 
photosensitizers that become activated by a specific wavelength of light. After excitation, the 
sensitizer, in its excited state, transfers its energy to molecular oxygen, forming reactive oxygen 
species. The cytotoxic products irreversibly oxidize essential cellular components, resulting in 
injury and necrosis of nearby tumor tissue [16-20]. Having an accessible treatment field in which 
to illuminate, this treatment method can selectively kill tumor cells within the treatment area 
without resulting in permanent damage to adjacent tissue. Thus eliminating the side effects 








Photodynamic therapy is a minimally invasive localized treatment modality based on three key 
components: photosensitizer, light and molecular oxygen [21].  The PDT treatment involves 1) the 
delivery of photosensitizers (PS) to tumors; 2) local excitation of tumor containing photosensitizer 
with a specific wavelength of light; 3) a photodynamic reaction between an optically excited 
photosensitizer and surrounding oxygen molecules, so as to produce reactive oxygen species 
(ROS).  This complex interplay between the photosensitizer and light can efficiently eradicate 
local tumors. 
The PDT action is described by two well defined mechanisms. Type I reactions produce free 
radicals or superoxide ions by the direct transfer of an electron from the photosensitizer to the 
substrate (cell membrane or other molecules), forming free radicals which interact with oxygen 
creating ROS [21]. Type II reactions generate singlet oxygen (1O2) and ROS by the means of 
energy transfer via collisions of the excited sensitizer with the surrounding oxygen molecules. The 
relative contribution from type I and II reactions depends on the type of photosensitizer used, the 
available tissue oxygen and the type of substrate (e.g., a cell membrane or a biomolecule), as well 
as the binding affinity of the sensitizer for the substrate [21]. The mutual consensus has been that 
singlet oxygen created by Type II reactions has been the primary method of destruction of nearby 
biomolecules [22-23]. 
A free radical is an electrically neutral atom or molecule with an unpaired electron. These, having 
one lone electron, become unstable and acquire electrons from neighboring molecules. Thus, the 
photodynamic reactions causing free radicals are known to cause structural damage to several key 
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biomolecules in cellular membranes and nucleic acids: carbohydrates, proteins, and lipids. 
Specifically, phototoxicity induced by the activation of photosensitizers can damage plasmatic or 
organelle membranes, causing membrane lysis and a disruption in cell homeostasis, leading to the 
destruction of treated cells [24]. 
 
 
Figure 1.1: Reaction kinetics of photosensitization leading to PDT. 
 
Reactive oxygen species 
ROS is a collective term that includes a set of different high energy molecules and radicals derived 
from the oxygen molecule. The set of ROS include singlet oxygen (1O2), superoxide (•O2
–), 
Hydrogen peroxide (H2O2), Hydroxyl Radical (HO•), etc. These highly energetic molecules or 
radicals, created by transfer of energy from the photosensitizers during illumination, has the 
potential to damage cells by oxidation of biomolecules such as lipids, proteins, nucleic acids and 
enzymes.  The specific damage to the cell is governed by the localization of these drugs in the 
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specific type of cells (tumor vs vasculature) as well as the specific subcellular compartments, such 
as the mitochrondia, cell membrane, nuclear membrane, lysozomes etc. [25-26] The damage 
caused by each individual species is also governed by its lifetime, which determines its diffusion 
length. For example, singlet oxygen has a lifetime of 4.4 µsec in water, as compared to 2.0 nsec 
for hydroxyl radicals, rendering it the freedom to move for a longer distance and increasing its 
potency [27-28].  Thus determination of the type and amount of each ROS produced is quite 
essential towards the success of this therapeautic modality. Optical methods based on fluorescence 
and absorbance have been regularly used for this purpose. Several fluorescencent dyes, like 
Anthracene dipropionic acid, 2'-7'dichlorfluorescein diacetate, Di-hydrorhodamine 123, Singlet 
Oxygen Sensor Green, etc., have been used for monitoring the changes in local concentration of 
the ROS, based on changes in fluorescence intensities due to oxidation by the ROS [28-29]. 
Although most of these dyes display a lack of absolute specificity towards a particular species, 
they do have different sensitivity towards each of these ROS, allowing for a fairly good estimation 
of the contribution from each of the ROS [30].    
 
Photosensitizers 
Photosensitizers are drugs that are activated by light whose wavelength is specific to its absorption. 
As mentioned before, upon irradiation, these molecules become excited and this results in the 
production of ROS, through non-radiative energy transfer to oxygen. An ideal photosensitizer 
should exhibit the following properties: [31-32] 
1. Strong absorption cross-section at longer wavelength, to increase the penetration depth. 
2. High quantum yield of ROS production. 
3. Good photostability: low photobleaching and degradation. 
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4. Minimal dark toxicity. 
5. High selectively towards tumor tissues. 
6. Fast clearance from the body.  
Several different photosensitizers have been used for various tumor therapies such as skin, head 
and neck, brain, gastroenterological, pulmonary, cervical, etc. [33]. The first generation 
photosensitizers mainly consisted of photofrin, which is a porphyrene derivative. The porphyrene 
based photosensitizers are the first and historically the most extensively used. Other kinds of non-
porphyrene based photosensitizers are broadly categorized as either chlorophyll derivative or dye 
[33].  
Photofrin was the first photosensitizer to gain FDA approval for several types of tumors. Since 
then numerous other photosensitizers such as temoporfin (Foscan), 5-aminolevulinic acid (5-ALA, 
Levulan), verteporfin (Visudyne), Methylene Blue, etc. as have been approved by the FDA. Some 
of the other photosensitizers such as HPPH, Chlorine e6, etc. have undergone clinical trials as well. 
The second generation photosensitizers are more promising, with improved properties, making 
them quite effective for clinical applications. However some of the drawbacks most commonly 
associated with photosensitizers are dark toxicity, low selectivity and specificity towards the target 
tissue, photo-degradation, slow clearance from the body, and pain associated with injecting some 
of the more hydrophobic drugs [34]. Currently, third generation photosensitizers that include 
modifications to previous drugs, such as conjugating antibodies, lipids, etc., are being explored 
[35]. Another area of interest is the utilization of nanocarriers of photosensitizers with the aim of 





Nanotechnology of drug carriers 
Nanotechnology facilitates the design of novel and effective drug delivery platforms that have the 
ability to overcome some of the potential drawbacks associated with the free drugs, be it for PDT 
or Chemotherapy [37]. Utilizing a nanoparticle design can limit the non-specific interaction 
between the free drug and plasma proteins, enzymes, immune system cells, etc. This can help 
reduce the changes in chemical or physical properties of the small molecule drugs, caused by 
degradation/breakdown, before its delivery to the intended location. Additionally, it offers the 
following advantages over free drugs [36-38]: 
1. Ability to simultaneously load multiple drugs and small molecule sensitizers into the 
nanoparticle.  
2. Capacity to control the drug release based on various stimuli such as pH, temperature, reducing 
agents such as glutathione, etc.  
3. Potential reduction in cytotoxicity. 
4. Enhanced plasma lifetime. 
5. Specific targeting to the particular cell line, and to its subcellular location. 
6. Synergistic loading withy image contrast agents. 
Over the past decade there has been significant progress in the design and development of various 
nanoparticles for the purpose of drug delivery. The attractiveness of the nanoparticle as a drug 
delivery vehicle lies in the flexibility offered by them in terms of its bulk and surface, which can 
be easily tuned during synthesis, as well as its toxicity properties. The most important 
considerations for the nanoparticle formulation is the material for the matrix and the functional 
groups. The nanoparticles can be engineered to load a specific drug for a particular application, by 
modifying its bulk and surface properties. The bulk properties such as density, elasticity, 
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hydrophobicity, etc., can be modified by choosing the appropriate materials for the matrix. The 
surface properties can be changed by modifying the surface and attachment of peptides, antibodies, 
or smaller targeting molecules, such as aptamers. The most commonly used matrixes for drug 
delivery are based on polymers, particularly hydrogels, due to their biocompatability and ease of 
engineerability [38]. 
Several types of, polymer and non-polymer, hydrogel based drug nanocarriers, such as silica, 
ormosil, PLGA, polystyrene, polymerized liposomes, pluronic co-polymers, polyacrylamide, 
polyacrylic acid, etc., have been utilized for therapeutic applications [36-38]. In this thesis, we will 
focus on polyacrylamide based nanoparticles as drug delivery vehicles. The polyacrylamide based 
nanoparticle has gained a lot of attention recently because of the ease in controlling the different 
chemical and physical properties, as well as its excellent biocompatibility and nontoxic properties. 
[39]. Polyacrylamide as a material has been frequently used in humans for different biomedical 
applications, the most prominent being its utilization as permanent filler for soft tissue 
augmentation during aesthetic facial surgery [40]. It has also been used for developing soft contact 
lenses. The polyacrylamide based matrix is inert and does not chemically interact with cells or 
tissues to cause any interference with their proper functioning, and neither does it lead to any 
perturbation in its vicinity. Polyacrylamide nanoparticles also act as an excellent choice for 
encapsulating different types of drugs and small molecules [41]. 
Up to now, the polyacrylamide based nanoparticles have already been used for drug delivery 
applications for both PDT and Chemotherapy [42-44]. Additionally this matrix has also been 
utilized for other applications, such as chemical sensing of ions and small molecules, tumor 
imaging etc. [41, 44-45]. They have also been applied as a visual contrast agent for delineating 
brain tumors [46].  
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Nanoparticle and tissue interaction 
Tumor cells, like healthy cells, need blood supply to grow. Without constant blood supply, solid 
tumor growth is limited to 2 mm in diameter. Such tumors may remain benign. However, in order 
to grow in size, tumors must develop their own blood vessel supply, to deliver nutrients and 
replenish oxygen [47]. Angiogenesis is the act of forming new capillary blood vessels. The tumor’s 
recruitment of new vasculature is initiated by angiogenic factors, such as endothelial growth factor 
(VEGF), platelet-derived growth factors (PDGF), and basic fibroblast growth factor (bFGF), 
which activate the proliferation of neighboring vessels [48]. This newly formed vasculature has 
little smooth muscle support and its vessels are more permeable than normal blood vessels. A solid 
tumor’s growth relies on the production of angiogenic vasculature; thus effective use of the leaky 
vasculature could facilitate tumor therapy. Angiogenic vasculature permeability and lack of 
lymphatic drainage allows for the accumulation of photosensitizer containing nanoparticles.   
Coating nanoparticles with the hydrophilic, water-soluble, polymer, polyethylene glycol (PEG), 
allows for longer plasma circulation times after nanoparticle administration [49]. PEG has been 
readily applied in different commercial, uses including incorporation into foods, cosmetics, 
ointments, pharmaceutics, etc. [50-51]. Long systemic circulation through tumor vasculature, 
having considerable fissures between endothelial cells in tumor blood vessels and tumor tissue, 
permits nanoparticle delivery and retention in tumors through “passive targeting” due to the 
“enhanced permeability and retention effect” (EPR) [52]. This unique quality, derived as a result 
of the angiogenesis process, allows for the selective extravasation into, and retention by, the tumor, 
of macromolecular/nanoparticle drugs used for tumor therapy. 
Potential enhancement of tumor drug delivery has been realized with the use of targeted cancer 
therapy, utilizing targeting molecules specific to tumor cell development and growth [53]. 
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Numerous targeted cancer therapies have been approved by the U.S. Food and Drug 
Administration (FDA), while others are undergoing clinical and pre-clinical tests show promise of 
success [54]. These therapies are designed using targeting molecules – antibodies and small 
molecule peptides - having distinct delivery methods. 
Most targeted cancer therapies have been developed with the intent of capitalizing on targets that 
play a key role in cancer cell growth and survival. Antibodies are used as delivery vehicles, 
engineered for the interaction with specific cell surface receptors [54]. Although being a very 
effective method, the large size and non-specific uptake of antibodies may prevent drugs from 
crossing cell membranes, limiting drug delivery to the outside of cells. Alleviating this problem 
associated with antibody targeting, small targeting molecule delivery of drugs can traverse cellular 
membranes, making this delivery method better suited for greater interaction with molecules 
located on the exterior and interior of cells [54]. Such therapy can be directed for the interference 
of gene expression, cellular function, signaling pathways, etc. “Small molecules” used for the 
delivery of therapeutic drugs include peptides. The 31-amino acid derived from the NH2-terminal 
fragment of the human high-mobility group protein 2 (HMGN2) [55], F3-peptide, selectively 
targets tumor blood vessels and tumor cells, due to their significant expression of nucleolin. This 
made the F3-peptide a desirable candidate for the delivery of photosensitizers in the work 
described in this thesis.  
The F3-tumor homing peptide binds to angiogenic vasculature and particular tumor cells 
expressing the cell surface receptor nucleolin [56-57].  Nucleolin is a multifunctional 
phosphoprotein ubiquitously dispersed throughout the nucleolus. Upon accumulation on the cell 
membrane surface, nucleolin can act as a shuttle protein, allowing for the internalization of drugs 
into the nucleus of tumor [58]. 
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Targeted therapies are designed to interact with specific molecules associated with tumor 
development, resulting in a reduced systemic toxicity, compared to standard chemotherapy and 
radiation treatments [56]. Using molecular targets reduces or eliminates collateral damage to 
healthy cells. This can contribute to improved patient comfort while undergoing treatment and 
better quality of life post-treatment. 
In Chapter two the development, characterization, and therapeutic application of Methylene Blue 
loaded nanoparticles on a rat glioma model in vivo is presented. The photosensitizer Methylene 
Blue was covalently conjugated to the nanoparticle matrix to prevent any leaching and non-specific 
staining. In vitro experiments demonstrated its high efficiency in producing reactive oxygen 
species as well as its cell killing ability. Further in vivo experiments were performed by first 
optimizing the different parameters of the therapy such as nanoparticle dose, effect of surface 
modification by attachment of targeting moieties such as F3-peptide, incubation time and the light 
fluence. The quantitative growth patterns of the glioma were determined through visual 
observation of the tumorigenic response to various treatments by the use of an animal cranial 
window model. The cranial window model was prepared by replacing a part of the rat skull with 
a glass window above the tumor. PDT treatments with Methylene Blue loaded nanoparticles 
produced significant adjournment of tumor growth over control groups, clearly demonstrating 
the advantages of nanoparticle-based PDT agents for the eradication of local tumors, leading to 
the potential palliation of the advancing disease. 
In chapter three we successfully demonstrate the application of another photosensitizer, (2-[1-
hexyloxyethyl]-2-devinyl pyropheophorbide-a) (HPPH), loaded nanoparticle towards an optimal 
treatment conditions for PDT. HPPH is a photosensitizer that has effective photodynamic 
efficiency and has been used for human clinical trials. The HPPH dye was incorporated into the 
13 
 
nanoparticle by post-loading. The hydrophobicity of the dye helps retain it inside the matrix, which 
is designed accordingly. Experiments on live cells show that these nanoparticles have minimal 
dark toxicity yet has excellent cell killing abilities when irradiated with light of appropriate 
wavelength. Both F3-targeted and non-targeted nanoparticles were used as well as different 
incubation times and light irradiation doses were applied to optimize the treatment parameters. In 
vivo PDT treatment on rat glioma, with windows, led to significant arrest of tumor growth over 
control groups. The results presented here demonstrate that PDT creates significant amount of 
necrosis and damages the vasculature that halts the tumor growth significantly. 
In chapter four we explore the possibility of combining multiple dyes such as, Methylene blue and 
Coomassie Blue, inside a nanoparticle, and predict its efficiency towards PDT by monitoring the 
ROS production from the mixture at different ratio. The rationale of using multiple dyes is to 
extend the application of the nanoparticles in guiding surgery in addition to PDT. We observe a 
significant decrease in the generation of ROS from the mixture with increasing concentration of 
Coomassie Blue dye. This can be attributed to the quenching of ROS production as well as its 
interaction with the dye, reducing its lifetime. These results show that such a selection of dye 
would not be optimal for combining PDT and visual delineation and highlights the need for an 
alternate strategy to achieve this goal.   
In chapter five we discuss some of the possible future direction. Following PDT we observe a 
significant arrest in tumor growth, however tumor re-growth is observed again at a later stage. This 
is attributed to the superficial nature of this treatment. Discussed in this chapter are the methods 
for improving this technique such as enhancing the ROS production using special NP design 
involving metal core. Additionally we also describe methods to monitor the in vivo dynamics of 
changes in oxygen concentration and ROS production as well as the cell killing and onset of 
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necrosis at the cellular level. Here we also propose the combination of surgery and PDT towards 
the treatment of glioma. That would involve development of multifunctional NP that can be used 
for visual tumor delineation and therapy as well, without compromising the efficiency of ROS 
production. The proposed treatment method of nanoparticle aided PDT would be most effective if 
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Choosing an appropriate and suitable photosensitizer is of upmost importance when designing a 
PDT agent. The ideal agent should exhibit chemical purity, nominal dark toxicity for the 
photosensitizer and its metabolites, high efficiency of tumor selectivity, high photochemical 
ability, activation at high absorbance wavelengths which achieve sufficient tissue penetration and 
are within the therapeutic window (600-900nm), and rapid system clearance to diminish 
photosensitivity [1-5].  
The above requirements, and especially the consequences of skin phototoxicity, led to second 
generation photosensitizers. Second-generation synthetic photosensitizers are recognized for 
having known chemical composition, a greater affinity for tumor selectivity, shorter periods of 
photosensitivity, higher yields of singlet oxygen, and an increase in penetration depth due to longer 
activation wavelengths in the range of 650-800nm [6]. 
Methylene Blue (MB), a second generation photosensitizer, is of particular interest with well-
established photochemical properties. This dye has a high quantum yield of singlet oxygen 
generation (~0.5) and is a highly efficient sensitizer for PDT [7]. Methylene Blue belongs to 
20 
 
the phenothiazinium family, allowing for increased efficacies of singlet oxygen production and a 
high molar absorption coefficient (εmax) ~ 82,000 M
-1 cm-1. Furthermore, this dye has excitation 
within the therapeutic window (600-900nm) allowing for greater penetration depths [3, 8-13].  
Methylene Blue has been utilized for a number of medical applications and therapies [14].  2013, 
over 13,000 entries for “Methylene Blue” have been accepted by the biomedical library PubMed, 
not including studies which were not covered by PubMed. Methylene Blue has made history as a 
histochemical stain, a biochemical reagent and a chief compound in the development of therapeutic 
agents for diseases ranging from microbial disease to cyanide poisoning [15-16]. In 1891, Paul 
Ehrlich used the dye as an anti-malarial drug during the Pacific War; later it was rejected for the 
staining side effects: turning the urine green and the sclera (whites of the eyes) blue [17-18]. This 
staining response of Methylene Blue provided the foundation of modern chemotherapy [15]. 
During the past decade, there has been considerable attention to the use of Methylene Blue as a 
potential drug for Alzheimer’s disease. Having the ability to inhibit the aggregation of the tau 
protein and the dissociation of amyloids, Methylene Blue shows promising results in halting the 
progression of Alzheimer’s dementia [19-20].  
Expanding the use of this therapeutic modality, there have been extensive experimental studies 
considering the application of Methylene Blue for photodynamic therapy in vitro [3,21], in vivo 
[22] and in clinical studies[4, 23-26], and it has been identified for having a promising potential 
for the treatment of cancer. Clinical PDT treatments and trials using Methylene Blue include basal 
cell carcinoma, melanoma, Kaposi’s sarcoma [27], and chronic periodontitis [28]. However the 
widespread use of Methylene Blue as a photosensitizer for clinical PDT has been limited due to 
its susceptibility to enzymatic degradation when delivered intravenously. 
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Methylene Blue can easily cross the cell membrane and anchor in the mitochondria [29-30], 
lysosomes [31] and double-stranded DNA [32]. It has been found that when Methylene Blue binds 
to the mitochondria it can traverse the matrix by the mitochondrial matrix proton potential [29]. 
Additionally increase in local concentrations of Methylene Blue induces the formation of 
Methylene Blue dimers, previously shown to be less effective in production of reactive oxygen 
species. [8-9]. This accumulation of Methylene Blue in the mitochondria reduces the compound -
induced by oxidation of the dye by NAD(P)H - to the colorless Leuko-Methylene Blue (LMB), a 
molecule with no photodynamic ability [12,22-23]. The physical uptake and reducing agent of 
Methylene Blue can be attributed to both the thiazine dye reductase found on the surface of 
endothelial cells and NADH/NADPH within the cells [33-35]. 
The ability to maintain the photosensitizing capability of Methylene Blue in a biological 
environment is critical for its application to PDT of cancer. Its incorporation into nanoparticle 
matrix composed of polymers such as polyacrylamide (PAA), silica, poly(lactic-co-glycolic 
acid), etc. can serve to embed the active form of the Methylene Blue photosensitizer, protecting it 
against enzymatic degradation [36]. Furthermore, nanoparticle surface modification can allow for 
enhanced and active targeting by attachment of a tumor specific homing moiety, e.g. the F3-
peptide, and coating it with polyethylene glycol (PEG) for longer plasma circulation [37].  
Loading of the Methylene Blue photosensitizer is achieved by physical encapsulation during 
synthesis or post loading after synthesis or even covalently linking the dye to the PAA nanoparticle 
matrix. The complex process of covalently linking the dye prevents any leaching related problems 
during in vivo studies. This loading method has been designed and tested, in serum solution, cells, 
and in vivo and has exhibited potential for future clinical applications [36]. 
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There are many advantages to the use of NPs for PDT due to its ability to reduce systemic toxicity 
of the drugs, improve the local delivery and specificity of drugs as well as enhance its plasma 
circulation time [38-43]. Engineering nanoparticles to lie within the desired diameter of 10-100 
nm avoid renal elimination and recognition by phagocytes [38-40]. Nanoparticle accumulation in 
brain tumor tissue and vasculature is achieved through “enhanced permeability and retention 
effect” (EPR), allowing macromolecules retention within tissue by way of leaky microvasculature 
and poor lymphatic drainage [41-44]. Nanoparticle matrix surface engineering can improve 
retention within tumor tissue with the attachment of a tumor specific homing moiety, e.g. the F3-
peptide and enhance plasma circulation (~24 hours) by coating the matrix with polyethylene glycol 
(PEG) [40].These novel delivery methods minimize side effects as well as enhances therapeutic 
efficiency. To avoid possible side effects caused by the accumulation of nanoparticles post-
treatment, biodegradable cross-linkers are incorporated into the nanoparticle matrix, allowing for 
slow biodegradation and bioelimination in vivo [45].  
Polyacrylamide nanoparticles containing Photofrin and surface-modified with F3-peptide have 
been utilized for specific targeting of the gliosarcoma cells. Nanoparticle targeting has also 
displayed high intratumoral NP uptake thereby increasing the phototoxicity – resulting in complete 
remission of tumor for 40% of the animals treated with F3-targeted Photofrin nanoparticles. While 
all control rats, including those treated with non-targeted NPs or free Photofrin, died within 2 
weeks [46]. 
In this chapter, the photosensitizer Methylene Blue was covalently conjugated to the nanoparticle 
matrix and used in in vitro and in vivo experiments to demonstrate its high proficiency in producing 
reactive oxygen species as well as its cell killing ability. In vivo experiments utilized glioma 
bearing rats adorning cranial windows allowing for direct serial inspection of various therapy 
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parameters of the such as nanoparticle dose, effect of surface modification by attachment of 
targeting moieties such as F3-peptide, incubation time and the light fluence.  
 
EXPERIMENTAL 
Nanoparticle synthesis  
Materials 
Methylene Blue succinimidylesther (MB-SE) was purchased from Emp. Biotech. Acrylamide 
(AA), 3-(acryloyoxy))-2-hydroxypropyl methacrylate (AHM), ammonium persulfate (APS), 
N,N,N’,N’-tetramethylethylenediamine (TEMED), sodium dioctylsulfosuccinate (AOT), Brij 30, 
were all acquired from Sigma-Aldrich (St Louis, MO). 3-(aminopropyl) methacrylamide 
hydrochloride salt (APMA) was purchased from Polysciences Inc. (Warrington, PA). Ethanol 
(95%) and hexane were purchased from Fisher Scientific. Phosphate-buffered solution (PBS) was 
made using a phosphate-buffered saline tablet from Sigma-Aldrich. F3-Cys peptide 
(KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC) was purchased from SynBioSci. The 
heterobifunctional PEG (MAL-PEG-NHS, 2k) was purchased from Creative PEG Works. All 
chemicals were used as purchased without further purification. 
 
Preparation of Methylene Blue nanoparticles 
Methylene Blue-conjugated polyacrylamide nanoparticles were prepared by a reverse 
microemulsion polymerization method [18]. A monomer solution was prepared by dissolving 
monomers, acrylamide and APMA, in PBS. A dye solution consisting of MB-SE and 
biodegradable cross-linker, AHM, was prepared and gently stirred for 2 hours at room temperature. 
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The monomer solution and the dye solution were sonicated and added to a deoxygenated hexane 
solution containing two surfactants, AOT and Brij 30. The two mixtures were emulsified by 
stirring for 20 min, followed by the initiation of polymerization by addition of a freshly prepared 
APS solution (10% w/v) and TEMED. The solution was then stirred under inert atmosphere, at 
room temperature, for 2 hours. After completing the polymerization, hexane was removed using a 
Rotavapor-P (Brinkmann Instruments) and the residue was suspended in ethanol. Excess surfactant 
and dye from the remnant mixture were removed by washing the particles with ethanol and 
distilled water through an Amicon ultra-filtration cell (Millipore Corp., Bedford, MA), with a 300 
kDa filter membrane under pressure (10–20 psi). The resultant nanoparticles were then freeze-
dried using a 5L ModulyoD freeze dryer (ThermoFisher Scientific). 
 
F3-peptide conjugation to polyacrylamide nanoparticles 
F3-peptides were conjugated to the surface of the nanoparticles for specific targeting to nucleolin 
expressed on the glioma cells. The freeze-dried PAA nanopartciles (50 mg) were dissolved in PBS 
(2.5 mL, pH 7.4) and bifunctional PEG (4 mg) was conjugated to the nanoparticle surface by 
amine-succinimidyl ester. This mixture was allowed to react under stirring condition for 30 min at 
room temperature before undergoing thorough washings using an Amicon centrifugal filter 
(Millipore, 100 kDa) thereby removing any unreacted ligands, and the final solution concentrated 
to ~20 mg/mL. Cystein tagged F3-peptide, F3-Cys peptides (0.06 µmol), were added to the 
concentrated nanosensor solution and gently stirred overnight ( >6 hours), at room temperature. L-
Cysteine aqueous solution was added to the mixture and stirred for 2 hours in order to deactivate 
the terminal site of unreacted PEG. The resultant F3-targeted MB-conjugated PAA nanoparticle 
solution was thoroughly washed with PBS and distilled water in an Amicon ultra-filtration cell 
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(Millipore Corp., Bedford, MA), and then freeze-dried with a 5L ModulyoD freeze dryer 
(ThermoFisher Scientific) until re-hydrated for experimental use. 
 
Surface modification of non-targeted nanoparticles 
Dye-conjugated PAA nanopartciles (50 mg) were dissolved in PBS (2.5 mL, pH 7.4). Bifunctional 
PEG (4 mg), was added to the nanoparticles solution and then the mixture was stirred for 30 min 
at room temperature.  A rinsing procedure was carried out, using an Amicon centrifugal filter 
(Millipore, 100 kDa), removing any unreacted ligands, and concentrated to ~20 mg/mL. Following 
the addition of PEG, an aqueous solution of L-Cysteine was added to the mixture and stirred for 2 
hours in order to deactivate the terminal site of PEG. The resultant non-targeted MB-conjugated 
polyacrylamide nanoparticle solution was thoroughly washed with PBS and distilled water in an 
Amicon ultra-filtration cell (Millipore Corp., Bedford, MA), and then freeze-dried with a 5L 
ModulyoD freeze dryer (ThermoFisher Scientific) until re-hydrated for experimental use. 
 
 





Dynamic light scattering measurements 
The size distribution of the MB-conjugated PAA nanoparticles in an aqueous solution was 
measured by dynamic light scattering (DLS, DelsaNano, Beckman Coulter, Inc., Brea, CA, USA). 
The surface charge of the MB-conjugated PAA nanoparticles in water was measured as a zeta 
potential value, using the above instrument. 
 
Quantification of dye loading 
The amount of dye in the nanoparticles was evaluated by absorption measurements, using a UV-
Vis spectrometer (UV-1601, Shimadzu, Scientific Instruments Inc., Columbia, MD, USA). The 
amount of photosensitizer loaded was calculated using the Beer-Lambert law. 
 
Reactive oxygen species detection 
ROS (reactive oxygen species) production from MB-PAA NPs was measured using Anthracene-
9,10-dipropionic acid disodium salt (ADPA) as a ROS (1O2) detection probe [47-48]. MB-
conjugated nanoparticles were suspended in PBS and mixed with ADPA in a cuvette and while 
under constant stirring the solution was irradiated at the excitation wavelength to determine 1O2 
generation using fluorescence spectroscopy (FluoroMax-3, JobinYvon/SPEX Division, 






For cytotoxicity studies, 9L glioma cells were plated on 96-well plates, at a density of 5000 cells 
per well, and incubated at 37oC overnight. For comparison, the cells were incubated with blank 
PAA, PEGylated PAA, and F3-targeted PAA nanoparticles at various concentrations (0.1, 0.2, 0.5, 
and 1.0 mg/ml) and left for 2 hours at 37oC with slow intermittent rocking. After incubation, to 
remove any unbound nanoparticles, the treated cells were carefully washed 3 times with fresh cell 
medium. The cells were further prepared using the MTT assay kit;  25 μl of 5.0 mg/ml 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in PBS was added to each well and 
left to incubate for 4 hours while slowly rocking. After 4 hours the solution was removed and 200 
μl of DMSO was added to each well, so as to solubilize the water-insoluble formazan crystals 
produced by the MTT cellular dehydrogenase activity in viable cells. The 96-well plate was 
covered with foil and left to steadily rock on a 55S single platform shaker (Reliable Scientific, Inc) 
overnight. To quantify cell viability of the treated cells, the absorbance spectra was analyzed using 
a microplate reader (SpectraMAXPlus 384, Molecular Devices LLC, Sunnyvale, CA) at 550nm 
and compared to untreated cells.  Each condition was performed using 12 wells so as to assure 
dependable results.  
 
Endotoxin detection 
Enodotoxin levels were measured using an Endosafe-PTS (Charles River) and following the LAL 
Assay [49]. A portable endotoxin meter has sterile cartridges for detecting endotoxin in aqueous 
samples. Within the device, a reaction between horseshoe crab blood extract, limulus amebocyte 
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lysate (LAL), and bacterial endotoxin, or with a membrane component of Gram negative bacteria 
can quantify bacterial endotoxins. All nanoparticle batches and samples were tested one hour prior 
to injecting the nanoparticle solution into the animal model during PDT treatment.  
Based on our experience with testing endotoxin levels for the nanoparticle samples, bacteria 
growth rates are highly sensitive to both time and temperature – longer exposure to solutions after 
hydration and warm temperatures can exacerbate bacteria growth. To avoid growth and 
contamination, the nanoparticle samples were rehydrated with minimal time intervals between 
hydration and injection; in addition, the sample was refrigerated at all times post rehydration, with 




Rat 9L gliosarcoma cells (Brain Tumor Research Center, University of California, San Francisco, 
CA) were routinely maintained in Rosewell Park Memorial Institute medium (RPMI) with 
400mg/L D-glucose and 292 mg/ml L-gluamine supplemented with 10% fetal bovine serum, 
100U/ml (3%) penicillin, 1mM sodium pyruvate, and 100 μg/ml streptomycin sulfate. Cells were 
grown at 37oC, 5% CO2 , 95% air, and 100 % humidity environment.  
Cells were plated on the 96 well plates for the MTT assay and on 35mm culture dishes with 





In vitro set-up 
Fluence dependent PDT  
To investigate the effects of PDT phototoxicity, a series of in vitro experiments were performed 
on rat 9L gliosarcoma cells. Glass cover slips were incubated with 1 mg/mL MB-loaded 
polyacrylamide nanoparticles (containing F3-peptide) for 1 hour, rinsed with appropriate cell 
media and placed in a temperature-controlled sample chamber at 37oC. Methylene Blue-mediated 
cytotoxicity was then monitored before and after illumination by labeling the cells with 5 μL 
Calcein-AM and 10 μL propidium iodide (PI) fluorescent stains. Fluorescent observations of 
Calcein-AM (excitation: 490nm, emission: 515nm) and PI (excitation: 536nm, emission: 617nm) 
were monitored for 30 minutes using a Perkin Elmer Ultra View Confocal microscope system 
equipped with an argon-krypton laser. Irradiation with the microscope laser, illumination was 
performed at 671 nm, for 1 minute intervals and stopped. The live/dead assay allows for obvious 
distinctions of viable/cytotoxic cells. In living cells, intracellular esterase converts the non-
fluorescent Calcein-AM into a green fluorescent Calcein, indicating viable cell. PI is barred by 
viable cells but can invade cells with damaged membranes. Upon irradiation, in a time-dependent 
manner, compromised cells release the green fluorescence of the Calcein-AM  through damaged 
membranes and permit the binding of PI to their nucleic acids - emitting red fluorescence. A series 
of images of the cells were sequentially taken for 30 minutes, in minute intervals, using an 
Olympus IX-70 confocal microscope. Upon completion of treatment, the objective was switched 
to a lower magnification so as to show that the treatment was localized to the illumination area – 
showing red stained, dead cells, which are surrounded by viable, green stained cells, just outside 
the illuminated area. At each time interval, the survival rate was presented as a percentage of the 
number of viable cells divided by the total number of cells (viable and non-viable). 
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Furthermore separate, fluency-dependent PDT studies were performed at illumination power 
density of 100 mW/cm2 and 222 mW/cm2. Pre-exposure images were taken using a 60X objective. 
The cells were exposed, for a total of 30 minutes, to a 671nm red diode laser (model 671RLMH1W, 
Changchun Dragon Lasers Co., Ltd) with light intensity of 100 mW/cm2 and 222 mW/cm2. Post-
exposure images were taken using a 20X objective, to observe the localized cellular damage. 
 
In vivo set-up 
Cranial window model 
The animal research protocol was reviewed and approved by the University Committee on Use 
and Care of Animals (UCUCA) at the University of Michigan, Ann Arbor. Biparietalcraniectomies 
were performed on 8-week old Sprague-Dawley male rats (Charles River Laboratory, Wilmington, 
MA). Rats weighing between 250 to 350 g were anesthetized and placed into a stereotactic frame. 
Rat 9L gliosarcoma cells were harvested in monolayers and following a full craniectomy 
suspended in media and the cells (105) were injected using a syringe micro-injector (Medfusion 
3500 syringe pump). The 9L cells were implanted in the forebrain at a depth of 1.5mm through a 
burr hole extending 1mm below the injection location to create a pocket for growth. To allow for 
serial inspection, a thin, round microscope cover slip was bonded to the cranial opening with 






Methylene Blue nanoparticle administration 
Nanoparticles were synthesized and formulated according to the previously described methods. 
The nanoparticles had a dye loading of 0.27% wt/(NP wt) and the dose administered is equivalent 
to 0.86 mg of MB/(kg of rat)..The stock solution was determined to have nominal endotoxin levels 
as determined by the LAL assay. Once the tumor radius reached 2-3 mm in diameter, 
photosensitizers in the form of free dye, or embedded within polyacrylamide nanoparticles, were 
administered intravenously through the right femoral vein using a programmable micro-injector 




Tumors in the BTW model were irradiated in a cross sectional manner, via the exposed tumor 
surface immediately beneath the window. In vivo light illumination was performed using a 671nm 
red diode laser (model 671RLMH1W, Changchun Dragon Lasers Co., Ltd) with tunable output 
power (0 – 1 W),to precisely expose at various fluency rates.  
The size of the laser beam was controlled by using a collimator (CSMA-8-B collimator, Newport 
Corp) so as to accurately control the light fluence for PDT. For all experiments, a constant beam 
diameter of 4 mm was used, while the distance between the cranial window and the collimator was 
fixed at 1 inch. 
Calibration of the laser was performed; it was tuned to the desired power, set to warm for 30 
minutes, and then checked again using a power meter to assure stability. After observing a 
complete hour of consistent power the laser was cleared for PDT illumination. It was not typical 
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to find fluctuations in power, and it was important to assure that the laser was working at the 
desired standard before treatment. 
 
Tumor size measurement  
Damage to sensitized tumor and brain parenchyma by photoirradiation was observed using a Sony 
digital camera. Daily photographs of the cortical surface through the BTW provided an evident 
depiction of the tumor growth patterns prior and post PDT treatments. Tumor growth patterns were 
then evaluated by delineating the tumor boundaries, based on the variations of pixelated coloration 
and measuring the total pixelated surface area of the tumor. The in vivo PDT efficiency was 
determined by measuring tumor surface area as seen through the BTW and comparing tumor 
growth patterns of individual animals and animal groups.  
 
 
RESULTS AND DISCUSSION 
The size of the surface-modified Methylene Blue-conjugated polyacrylamide nanoparticles was 
measured using a particle size analyzer. The DLS data indicated that the mean diameter of the 
modified nanoparticles in solution was 55.0 (± 5.0) nm, Figure 1, similar to that of the unmodified 
nanoparticles. Thus modification of the surface by the attachment of PEG or targeting ligands had 
no significant effect on the size of particles in solution. These nanoparticles fall within the optimal 
range of 10-100nm which has proved to be very effective for in vivo applications. This is because 
nanoparticles greater than 10nm have the ability to avoid clearance by the kidney, allowing for 
prolonged and elevated circulatory levels, and nanoparticles smaller than 100nm avoid entrapment 
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by phagocytes [51-52]. Furthermore, leaky angiogenic vasculatures have fenestrations that 
improves the penetration phenomenon of enhanced penetration and retention (EPR) effect, 
allowing nanoparticles to be delivered and to accumulate in tumor tissue more readily than in the 
surrounding healthy tissue [41-44, 53]. 
The F3-modified nanoparticles have a surface charge of +12 (±1) mV, whereas the non-targeted 
(surface PEGylated) nanoparticles have a charge of +2 (±1) mV, in comparison to the unmodified 
nanoparticles that have free amine groups on the surface, having a charge of +14 (±3) mV. The 
non-targeted nanoparticles have a near neutral surface charge due to the presence of the neutral 
PEG molecules on the particle surface. However the F3-targeted Methylene Blue-conjugated 
polyacrylamide nanoparticles display a positive surface charge because the cationic F3-peptide on 
the surface of the nanoparticle has high positive charge. 
The amount of dye encapsulated in the nanoparticle was determined by comparing the fluorescence 
and absorbance spectra of a data set of known concentrations of nanoparticles in water with precise 
amounts of dye in addition to nanoparticles in water. It was determined from the absorbance 
spectra of the covalently linked Methylene Blue polyacrylamide nanoparticles that the dye 








Figure 2.2: (A) Size distribution of polyacrylamide nanoparticles in solution using 
dynamic light scattering measurments. ROS production measurement of (B) 
Methylene Blue free dye in DI water and (C) Methylene Blue polyacrylamide 
nanoparticles. Peak excitation for Methylene Blue was found at 678 nm: linear 
fitted plot of fluorescence change in ADPA as a function of irradiation time.  
 
The efficiency of photodynamic therapy depends directly on the photosensitizer’s ability to 
produce reactive oxygen species (ROS), on the availability of molecular oxygen, on the light 
fluency (intensity and duration), as well as on the photosensitizer concentration at the treatment 
area. Figure 2.2 shows the generation of ROS of Methylene Blue dye and Methylene Blue 
encapsulated in nanoparticles. The ROS production rate constant was measured by the 
fluorescence decay of ADPA and was found to be 5.5x10-4/s for 1.0 µM free Methylene Blue dye 
in PBS. For Methylene Blue 0.37% wt/(NP wt) encapsulated in nanoparticles the rate constant was 
4.35x10-4/s.  The capability of the targeted nanoparticles to produce reactive oxygen species and 
kill cells was optimized through in vitro experiments [36]. Experiments performed in vitro 
provided a foundation of preliminary studies for the in vivo PDT protocols: nanoparticle delivery 
conditions, dose and optimal light fluence, and rudimentary glioma growth rates [36, 50]. 
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To investigate the PDT efficiency of Methylene Blue-conjugated polyacrylamide nanoparticles in 
in vitro experiments, MTT assays were carried out under conditions of various doses of 
nanoparticles. F3-targeted and non-targeted nanoparticles were added with increasing 
concentrations for survival assessment as determined by the MTT assay. The cytotoxicity of the 
nanoparticles was determined by the conversion of MTT to formazan via mitochondrial oxidation. 
Cell survival rates showed no significant differences among cells treated with Methylene Blue 
polyacrylamide nanoparticles (in the dark) and the control (cells only).  The average cell survival 
rates exhibited a higher than 97% viability, up to 1mg/ml nanoparticle concentration (Figure 2.3). 
Overall, the treated cells endured no detectable cytotoxicity as a result of being treated with the 
Methylene Blue polyacrylamide nanoparticle solution (in the dark), ensuring that viability 
variances in PDT experiments will not be compromised by dark toxicity produced by the 
nanoparticles.  
 
Figure 2.3: Examination of cytotoxicity using the MTT assay. Cell viability of 9L 
gliosarcoma, evaluated after 24 hours incubation with varying concentrations of 
F3-targeted and non-targeted Methylene Blue nanoparticles.  Cell survival rates 
indicated no measurable variance between nanoparticle concentrations (0.1, 0.2, 





























To ensure that the ROS was generated as a response to light activating the dye encapsulated in the 
nanoparticle matrix, dye leaching needed to be examined. It is imperative to test dye leaching 
because photosensitizers outside the nanoparticle can interact with cellular surface proteins and 
organelles in vitro; furthermore, enzymatic degradation of the leached out Methylene Blue dye 
might alter the optical properties of the dye during intraoperative in vivo applications. In order to 
survey the dye leaching, the Methylene Blue content in the filtrate separated from the nanoparticles 
by centrifugation filtration was measured, using UV-Vis absorbance spectra. There was no 
detectable absorbance at 668nm, verifying negligible dye leaching of Methylene Blue out of the 
Methylene Blue polyacrylamide nanoparticles. This verifies that the detected reaction between the 
Methylene Blue dye and the ROS must occur within the nanoparticle. It also verified that 
covalently linking the Methylene Blue dye to the nanoparticle matrix completely eliminates dye 
leaching, thus ensuring the delivery of the full pay-load of photosensitizer to cells in vitro or to 
tumor sites in vivo. 
To investigate the fluence rate dependence of PDT phototoxicity, a series of in vitro experiments 
were performed on rat 9L gliosarcoma cells. Using the optimized protocols for the live/dead assay, 
9L cells were irradiated at two separate light intensities, 100 mW/cm2 and 222 mW/cm2, using an 
excitation wavelength of 671 nm. A series of images of the cells were sequentially taken over 30 
minutes, in 1 minute intervals, using an Ultra-View confocal microscope (Figure 2.4). 
Two experiments were carried out with the intention of examining cytotoxicity rates at different 
laser fluencies; their images are displayed side-by-side (100 mW/cm2: Figure 2.4a-e; 222 mW/cm2: 
Figure 2.4f-j). Before light irradiation, all cells were stained by Calcein-AM, showing green 
fluorescence, verifying cell viability for both experiments (Figures 2.4a, 2.4f). After 5 minutes of 
irradiation, the cells exposed to the greater fluence rate show the earliest indication of cell death, 
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by the presence of PI-stained red nuclei (Figure 2.4g) while the lesser fluence rate shows no sign 
of cellular death (Figure 2.4b). After completing 10 minutes of illumination, the cells exposed to  
the higher illumination fluence show a convincing display of cellular death (Figure 2.4h) and 
continuously improve in displaying cytotoxic effects throughout the 30 minute experiment (Figure 
2.4j). Similarly, the lower fluence rate displayed primary signs of cell death at 10 minutes and the 
cellular cytotoxicity intensified between 20 and 30 minutes of illumination (Figures 2.4d, 2.4e).  
 
Figure 2.4: Confocal images of 9L cell lines treated with Methylene Blue-
conjugated PAA nanoparticles. Intensity dependent cytotoxicity, induced by F3-
targted Methylene Blue PAA nanoparticles and laser irradiation. The 9L 
gliosarcoma cells were incubated with Methylene Blue nanoparticles and irradiated 
with fluencies of 100 mW/cm2 and 222 mW/cm2. Images were taken (a) before 
light exposure; (b-e) over 30 min of light exposure at a dose of 100 mW/cm2. 
Images were taken (f) before light exposure; (g-j) over 30 min light exposure at a 
dose of 222 mW/cm2. Cytotoxicity was monitored by labeling the cells with 
Calcein-AM (green, for viable cells) and propidium iodide (red, for dead cells). 
Measurements taken on a confocal microscope. 
 
Although the composite confocal images may seem to qualitatively display similar cytotoxic 
abilities for both experiments, a quantitative analysis displayed a more refined picture of 
cytotoxicity on the treated cells (Figure 2.5). This cell viability experiment indicates that a higher 
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fluence rate of laser light has the ability to achieve a faster rate of cellular cytotoxicity, however 
nearly all cells were killed after 15 min of irradiation with the above given dose. 
 
Figure 2.5: Cell viability assessment for the phototoxic effects of F3-targeted 
Methylene Blue polyacrylamide nanoparticles on a 9L cell line. Fluency dependent 
PDT efficiency at light doses of 100 mW/cm2 and 222 mW/cm2, over the course of 
30 minutes of illumination.  Cells exposed to a higher fluency responded with a 
more rapid cellular death than for a lower fluency.  
 
From the above, one observes that cells exposed to a higher fluence rate display a significantly 
increased rate of cellular damage, which is induced within a shorter time frame, this was all 
signified by a rapid release of Calcein-AM (green) through the compromised cellular membrane 
allowing for the incorporation of PI (red) into the nucleus.  These results demonstrate the light- 
dose dependency of PDT cytotoxicity, thus indicating that further optimization of the exposure 
time and fluence rate could better enhance the PDT efficacy. 
Activation of the photosensitizer in the presence of oxygen is highly cytotoxic, however the short 
lifetimes (<0.04s) and the short diffusion distances (<0.02m) of the ROS allows the treatment 
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to be restricted to the nearby cells, tissue and vasculature where the illuminated photosensitizers 
are present [54]. To further demonstrate the localization and specificity achieved using this 
localized PDT therapy, a small section of the cells were irradiated using a 60X objective and then 
the images were captured post-irradiation, using a lower magnification objective, with the 
irradiated area on the right side of the image (Figures 2.6c, 2.6f). The focused illumination induced 
cell death only to the cells within proximity to the laser beam; whereas adjacent cells, containing 
methylene blue nanoparticles but not irradiated, display no detectable loss of membrane integrity, 
as indicated by their green fluorescence. In addition to these localization tests, cells not treated 
with Methylene Blue-linked polyacrylamide nanoparticle showed no detectable cytotoxicity when 
exposed to laser irradiation for 30 minutes, at varying fluence rates, suggesting that solely 
illuminating the cells is not cytotoxic to these cancer cells.  
 
Figure 2.6: Confocal images of 9L cell lines treated with Methylene Blue-conjugated PAA 
nanoparticles, before and after laser illumination. Cell viability was monitored by labeling 
cells with Calcein-AM (green, viable cells) and propidium iodide (red, dead cells). Images 
were taken before illumination at 60X magnification. Post-illumination images were taken 
at a lower magnification to illustrate that cellular death merely occurred in the area exposed 
to laser irradiation.  
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When performing localized PDT in vivo, the efficacy of singlet oxygen generation and tumor 
eradication is directly proportional to the intratumoral concentration of the nanoparticle containing 
the photosensitizing agent. In order to improve therapeutic efficacy of this treatment it is 
imperative to understand the kinetics of the targeted nanoparticle, more specifically the incubation 
time needed to permit the highest concentration of NP at a specific site. Transvascular transport 
and accumulation of the nanoparticles within the glioma domain can be confirmed in vivo through 
delineation experiments. By performing intravital staining experiments using contrast dye 
containing nanoparticles for delineation of the implanted neoplasm, direct observation of color 
variations following the intravenous injection of dye enhanced polyacrylamide nanoparticles can 
be visualized through the rat cranial window model. Subsequently, this visualization will quantify 
of the optimal irradiation time, i.e. the incubation time with greatest accumulation of nanoparticles.  
Brain tumor margins are poorly defined when looking through the BTW model. In previous 
studies, our group performed tumor delineation studies using Coomassie Brilliant Blue (CB) 
loaded polyacrylamide nanoparticles [55]. Coomassie Blue is an intensely blue colored dye agent 
and when covalently linked to the polyacrylamide nanoparticles it can be used as a color contrast 
agent to aid in intraoperative tumor margin delineation. After intravenous injection of the 
Coomassie Blue polyacrylamide nanoparticles into each rat’s femoral vein, the amount of 
nanoparticles bound to the glioma tissue can be monitored in vivo, on a microscopic level, through 
the rat cranial window model. A quantitative evaluation of tumor delineation resulting from free 
Coomassie Blue dye, non-targeted CB-linked nanoparticles, and F3-targeted CB-linked 
nanoparticles was performed using a Coomassie Blue dose of 35mg/kg (NP dose was 500mg/kg). 
Each treatment resulted in rapid brain tumor delineation, with a more significant color contrast 
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resulting from the use of nanoparticles – a better defined tumor area and strong visual contrast 
over longer time durations.  
This delineation study performed by the Kopelman group is applicable to determining the optimal 
times between the administration of the drug (Methylene Blue, in the form of free dye and 
encapsulated in nanoparticles) and the illumination time. Determining peak accumulation of 
Coomassie Blue nanoparticles within the brain tumor tissue will give insight as to the possible 
biodistribution of Methylene Blue nanoparticles in the tumor tissue when used for PDT treatment. 
The Coomassie Blue delineation study revealed peak accumulation of Coomassie Blue free dye at 
30 minutes, vs. 120 minutes for non-targeted CB-linked NP-treated animals, while the color 
contrast for the F3-targeted Coomassie Blue nanoparticles continued to intensify throughout the 
end of the six-hour experiment. The contrast intensification over time induced by F3-targeted 
nanoparticles, compared to non-targeted NPs, may be due to the active targeting of the F3-peptide, 
i.e. their interactions with the nucleolin receptors which are highly expressed on 9L glioma cells 
and on the angiogenic vasculature [50-51] 
 
When the brain tumor radius reached 3 mm in diameter, photosensitizers in the form of free dye 
and embedded within polyacrylamide nanoparticles were administered intravenously via the 
femoral vein. The Methylene Blue-conjugated nanoparticles were administered at a dose of 300 
mg/kg, which corresponds to a dose of 0.86 mg MB/kg. This dose has proved to be safe in 
accordance with previous nanoparticle optimization and toxicology studies [50, 55]. The time 
interval between nanoparticle administration and light illumination was set at 105 minutes, based 
on previous incubation studies investigating nanoparticle accumulation at the treatment location 
and the light dose was fixed at 180 J/cm2 [50]. To monitor tumor growth patterns, daily 
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photographs of the cortical surface through the BTW on the rat model, prior and post PDT 
treatments, were taken (Figure 2.7). 
 
 
Figure 2.7: A series of cranial window pictures of a rat with an implanted 9L glioma, 
before and after the PDT, using F3-Methylene Blue polyacrylamide nanoparticles and a 
time interval of 105min between nanoparticle injection and light illumination. The dotted 




Figure 2.8: (A) Photograph displaying therapy setup. Rats with BTW are 
positioned in sterotactic frames with distance between cranial window and laser 
collimator fixed at 1 inch. Photographs of a tumor as seen through the BTW (B) 
before therapy and (C) during irradiation with a 671nm laser.  
 
Systemic incubation times of 105 minutes and 24 hours were selected to further explore the 
consequence of incubation time on the PDT effects on tumor growth patterns. The goal of this 
work was to establish defined incubation conditions for use of future PDT experiments and 
optimize predictive functions of the treatment. Incubation times were chosen based on the 
Coomassie Blue delineation studies performed by the Sagher and Kopelman groups, concluding 
maximal accumulation of both targeted and non-targeted nanoparticles occurring at 120 minutes 
post-injection [50]. To guarantee light exposure during the greatest accumulation of nanoparticles 
within the brain tumor, laser illumination started at 105 minutes post-nanoparticle injection and 
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preceded for 30 minutes – ensuring irradiation occurred 15 minutes before and after the optimal 
irradiation window. The time interval of 24 hours between nanoparticle administration and light 
illumination was based on previous studies using HPPH post-loaded polyacrylamide nanoparticles 
on mice bearing Colon26 tumors [56]. 
The tumor growth curve (Figure 2.9) demonstrates that for equivalent protocols with varying 
incubation times, the PDT protocol with 105 minute incubation was more effective at inducing 
phototoxicity than the one with 24 hrs. Retardation in tumor growth was evident six days post-
treatment and significantly noticeable differences in tumor size was seen through day ten. Thus, 
irradiation performed at 105 minute post-drug injection resulted in a more favorable treatment 
outcome when compared to the 24 hour incubation.  
 
 
Figure 2.9: Incubation time dependent effects of photodynamic therapy treatment. F3-
targeted Methylene Blue polyacrylamide nanoparticles were intravenously injected, and 
once completing 105 minutes or 24 hours of systemic incubation, the tumors were 

























Variation in Incubation Time






Figure 2.10: Daily photographs of the cortical surface depict tumor growth, images 
taken through brain tumor windows on rat models. Animals groups receiving 
irradiation experienced a fluence dose of 180 J/cm2 using 671 nm laser.  
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Evaluation of the effects of each treatments group on the tumor growth patterns was accomplished 
and is presented in Figure 2.10. Control animals were not injected with photosensitizer, nor were 
they exposed to laser light; this group was purely acting as a control group for determining tumor 
growth patterns post tumor implantation surgery. Animals treated with laser illumination and free 
photosensitizer were dosed with 0.86 mg/kg of the Methylene Blue free dye and the effect on 
tumor tissue was assessed after 105 minutes of systemic incubation of the nanoparticles and  
irradiating animals with laser light (180 J/cm2). The time course for incubation was empirically 
determined using tumor delineation results acquired by the Sagher and Kopelman groups and 
Figure 2.9 [50, 55]. 
As expected, the PDT treatment with Methylene Blue free dye did not affect the tumor growth 
when compared to the control group. This was probably due to the ability of enzymes to reduce 
free Methylene Blue to the photochemically-inactive form of Leuko-Methylene Blue, resulting in 
the loss of photodynamic activity. To study the difference in nanoparticle circulation and 
accumulation between targeted and non-targeted Methylene Blue nanoparticles, animals were 
injected with 0.86 mg/kg of the particles with dye loading of 0.37% wt/(NP wt). After the 
completion of nanoparticle administration, systemic incubation time of 105 minutes was followed 





Figure 2.11: Effect of PDT treatment delivered 105 minutes after injection of Methylene 
Blue F3-targeted nanoparticles, Methylene Blue PEGylated nanoparticles and Methylene 
Blue free dye. The control animal was not administered with photosensitizer or exposed to 
the laser illumination. Another control animal group treated with light illumination showed 
the same tumor growth trend as the “no treatment” control animal group. 
 
Overall there were significant statistical differences in median tumor size between the control and 
Methylene Blue free dye treatment, versus that by Methylene Blue polyacrylamide nanoparticles, 
whether F3-targeted or non-targeted. When treating the tumors with Methylene Blue 
polyacrylamide nanoparticles there is a significant arrest of tumor growth. However, the 
insignificant differences between the two delivery methods, F3-targeted and PEGylated verses 
PEGylated, signifies the use of F3-peptide did not significantly improve the PDT outcome. The 
similar growth trends of the targeted and non-targeted PEG polyacrylamide nanoparticles confirm 
that our particles effectively accumulated in the tumor sites via passive targeting of EPR as well. 
This clearly demonstrates the advantages of NP-based PDT agents. We also notice that the tumor 




































animals treated with PEGylated Methylene Blue polyacrylamide nanoparticles. This is probably 
because the tumor was illuminated from only one direction, i.e. through the cranial window, due 
to constraints imposed by the BTW. However in a clinical setting, where light can be directed at 
all angles for intra-operative PDT, we may expect a significantly higher efficacy. 
Tumor growth patterns were calculated by measuring the surface area of the tumor tissue as seen 
through the BTW. Surface area dimensions were taken by quantifying tumor tissue remaining post-
irradiation and normalizing to the tumor area measured on PDT-treatment day (day 0). Post-
treatment areas of necrotic tissue were recorded, though not included in those data sets; however 
this subsequent outcome of treatment proves important in the evaluation of treatment success.  
 
Figure 2.12: Post-PDT treatment necrotic tissue measurements for tumors treated with F3-
targeted Methylene Blue polyacrylamide nanoparticles verses non-targeted (PEGylated) 
Methylene Blue nanoparticles. Both treatment groups express similar necrotic formation 
and regression patterns with a greater formation of necrotic tissue for non-targeted 
Methylene Blue nanoparticles. 
 
Figure 2.12 compares the surface area measurements of necrotic tissue for F3-targeted and non-
targeted Methylene Blue polyacrylamide nanoparticles. The day of treatment and one day post-
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treatment showed no detectable traces of necrosis, however outstanding amounts of necrotic tissue 
appeared two days post-treatment and dissipated through day six as the necrotic tissue was no 
longer visible due to microglia and astrocytes (glial cells) removing the damaged tissue in addition 
to tumor tissue regrowth.  
 
Figure 2.13: Gross specimen from animal model, excised 10 days post-PDT therapy. 
Representation of brain tumor for animal groups (A,B) without photosensitizer or laser 
illumination, and (C,D) animals receiving non-targeted Methylene Blue nanoparticles (105 
minute incubation time) with irradiation fluence dose of 180 J/cm2 using a 671 nm laser. 
 
Optical penetration depth in tissue is the distance through which the radiant power decreases to 
1/e or 37% of its initial value [57]. Beyond this depth, tissue is exposed to laser light of a lower 
intensity, which still may be adequate for PDT. Methylene Blue dye has a long absorption 
wavelength (λmax = 670 nm) allowing for good penetration depth of laser light in live tissues, 
however the penetration of light through the tumor is dependent on the characteristics of the treated 
tissue. Laser light at 631 nm can achieve a penetration depth of 1.5 ± 0.43mm in brain tissue and 
2.9 ± 1.5mm in brain tumor tissue [58]. The rat models used in these experiments contained tumor 
implants extending into the cortex – a depth which may exceed the penetration depth achievable 
by our 671 nm laser. This limitation resulted in incomplete eradication of the base of the tumor, 
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resulting in detectable growth patterns days after treatment. However, PDT is still expected to be 
effectively applied as a post-surgical adjunctive treatment because the microscopic residual tumor 
tissue is within effective range. 
 
CONCLUSIONS 
Our group demonstrated effective eradication of 9L glioma cells using both targeted and non-
targeted nanoparticles. The nanoparticles encapsulated the Methylene Blue photosensitizer in a 
hydrogel matrix with an average size of 55 nm, containing approximately 0.27% dye by weight. 
These photosensitive nanoparticles proved suitable for the eradication of 9L glioma both in vitro 
and in vivo. Visual observations through the BTW model allowed for serial inspection and efficacy 
of various treatment protocols investigating photosensitizer delivery and incubation time between 
nanoparticle administration and laser treatment. Quantitative tumorigenic responses and growth 
patterns presented a more favorable treatment outcome for animals receiving treatment 105 
minutes after nanoparticle administration, over the animals receiving a 24 hour incubation time. 
When investigating photosensitizer delivery methods, both the targeted and non-targeted 
Methylene Blue nanoparticles had comparable necrotic development and delays in tumor 
progression post-treatment. With substantial improvements in tumor response to treatment over 
control groups, advantages of nanoparticle-based PDT agents prove advantageous for the 
eradication of local tumors. 
Such photoreactive nanoparticles have the potential to be used for photodynamic therapy as an aid 
to neurosurgery. The dye-loaded nanoparticle, administered just prior to surgery would help 
eradicate residual tumor after maximal resection, thereby minimizing the need for adjuvant 
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therapy. Such a novel approach has the potential to advance surgical and adjuvant therapy towards 
a major breakthrough in the treatment of brain tumors. We believe this method can efficiently and 
rapidly eradicate local tumors, lead to the eventual palliation of advanced disease or result in the 
cure of early disease [59].  
 
(This chapter was written with the intent of future publication) 
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Evaluating the Effect of HPPH Mediated Photodynamic 
Therapy for Arresting Glioma 
 
INTRODUCTION 
While the disease is well-localized and neoplastic growths are small, highly localized therapies 
have the potential advantage of reduced adverse side-effects and nominal damage to surrounding 
tissue, nerves, and major blood vessels – not a routine feature of systematic chemotherapy or 
invasive surgery [1-3]. An example of a localized therapy harnessing these benefits is 
photodynamic therapy (PDT). PDT is a minimally invasive treatment that involves the activation 
of a photosensitizer by light of a specific wavelength that generates cytotoxic reactive oxygen 
species, ensuing in direct destruction of tumor cells [4]. It has been proven to be an effective 
localized treatment for a range of solid tumors and has demonstrated anti-tumor responses [5-9].   
Depending on the region in which one is performing PDT, photosensistizers can be administered 
topically, intraperitoneally, or intravenously – the latter being required for the treatment of tumors 
situated in the brain [10-11]. Following the localization of nanoparticles in the treatment region, 
irradiation at wavelengths specific to the photosensitizer generates reactive oxygen species, which 
are cytotoxic to surrounding tumor cells [4]. In addition to dependence on the local level of 
molecular oxygen, the biological effects of PDT are directly correlated to the dynamic interaction 
between the laser light and the photosensitizer. A requirement for an ideal photosensitizer intended 
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for the treatment of cerebral tumors is that it should exhibit strong absorption in the therapeutic 
window (600-900 nm). Light at this wavelength can effectively penetrate tumor tissue in order to 
eradicate dysplastic cells undergoing therapy [12]. The photosensitizer should also have the 
following characteristics: systemically non-toxic in the dark, chemical purity, maximal efficiency 
of tumor selectivity, high photochemical ability, and being rapidly excreted from systemic tissue 
to avoid post-treatment photosensitivity [13-16]. 
The first FDA approved photosensitizing agent for treatment of cancer belongs to the poryphrin 
family, porfimir sodium (Photofrin). Photofrin is known as a first-generation photosensitizer and 
has been used for the treatment of papillary bladder cancer, cervical cancer, endobronchial cancer, 
esophageal cancer, lung cancer, and Barrett’s esophagus before 2003 [12, 17-21]. However, 
Photofrin has numerous intrinsic limitations, making it less desirable for clinical applications, 
specifically its low molar absorption coefficient (1,170 M−1 cm−1) as well as cutaneous 
photosensitivity resulting from retention of residual photosensitizer [22-23]. 
These limitations have been the major impetus behind the synthesis of a second-generation 
photosensitizer developed at the Rosewell Park Cancer Institute (RPCI), 2-devinyl-2-(1-
hexyloxyethyl) pyropheophorbide (HPPH). HPPH has a peak absorbance in the red region of the 
visible spectrum, at 665 nm, with a large molar extinction coefficient (εmax) ~ 47,000 M
-1 cm-1 [24] 
and a high quantum yield of singlet oxygen generation (~0.48) [8, 25-26]. These chemical 
properties make HPPH a promising photosensitizer for in vivo PDT treatment. In contrast to most 
porphyrin-based agents, such as Photofrin, an absorbance at 665 nm enhances tissue penetration 
and did not show any significant prolonged skin photosensitivity in the patients [25]. HPPH had 
been approved for use in several clinical trials and has undergone Phase I trials involving basal 
cell skin cancer, head and neck cancer, and for treating dysplasia, carcinoma of the oral cavity, 
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and carcinoma of the oropharynx [27-29]. HPPH is currently in Phase II trials for lung cancer and 
Phase I/II trials for esophageal cancer, both showing effective anti-tumor responses [3, 19, 24, 30]. 
Localization and distribution of the photosensitizers in dysplastic cells is highly dependent on the 
photosensitizer’s solubility and lipophilicity. Diffusion through lipid barriers of the cellular 
membrane and crossing into endocellular sites, like the nucleus, of the cell, requires that the drug 
be lipophilic in its free form [31]. HPPH is an extremely hydrophobic photosensitizer, 
consequently it requires a 1% Tween 80 / 5% dextrose formula to be used under physiologic 
conditions [32]. Systemic administration of such photosensitizers has been enabled through 
advancements in nanotechnology. Inherent solubility limitations require that HPPH be 
incorporated into a nanoparticle composed of a hydrogel matrix such as polyacrylamide (PAA). 
Biocompatible, polyacrylamide nanoparticles have previously been reported as promising vehicles 
for therapeutic photosensitizer delivery to tumor tissues [33-40]. The narrow hydrogel pores of the 
polyacrylamide matrix protect the active form of the photosensitizer from enzymatic degradation, 
but do not hinder the free flow of molecular oxygen – an important element required for the 
photochemical reaction of PDT. This loading method allows stable delivery of the hydrophobic 
photosensitizer under physiologic conditions and avoids systemic solubility limitations [41].  
Nanoparticle (NP) surface modifications allow enhanced and active targeting by attachment of a 
tumor specific homing moiety, e.g. the F3-peptide, and coating the NP with polyethylene glycol 
(PEG) for longer plasma circulation (~24 hrs) [42]. Further selective uptake of the nanoparticles 
by tumor tissue ensues by the “enhanced permeability and retention effect” (EPR), allowing tissue 
retention of macromolecules by way of leaky microvasculature and poor lymphatic drainage [4, 
43-44]. Designing nanoparticles between 10-100 nm in diameter is advantageous in order to utilize 
EPR. Molecules larger than 10 nm have the ability to bypass renal elimination, allowing for a 
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Nanoparticle synthesis  
Materials 
The 2-devinyl-2-(1-hexyloxyethyl) pyropheophorbide (HPPH) was supplied by Roswell Park 
Cancer Institute (Buffalo, NY). Sodium dioctyl sulfosuccinate (AOT), Brij 30, Acrylamide (AA), 
ammonium persulfate (APS), N,N,N’,N’-tetramethyl ethylenediamine (TEMED), and glycercol 
dimethacrylate (GDMA) were all acquired from Sigma-Aldrich (St Louis, MO). The 3-
(aminopropyl) methacrylamide hydrochloride salt (APMA) was purchased from Polysciences Inc. 
(Warrington, PA). Ethanol (95%) and hexane were purchased from Fisher Scientific. Phosphate-
buffered solution (PBS) was made using a phosphate-buffered saline tablet from Sigma-Aldrich. 
F3-Cys peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC) was purchased from 
SynBioSci. The heterobifunctional PEG (MAL-PEG-NHS, 2k) was purchased from Creative PEG 
Works. All chemicals were used as purchased without further purification. 
 
Preparation of HPPH nanoparticles 
HPPH post-loaded polyacrylamide nanoparticles were prepared by a reverse microemulsion 
polymerization method [18]. Then, HPPH (20 mg/ml in DMSO) was added to blank 
polyacrylamide nanoparticles suspended in 1% Tween 80 solution. The mixture was then stirred 
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under inert atmosphere, at room temperature, for 2 hours. Excess photosensitizer and DMSO were 
removed from the remnant mixture by washing the particles with ethanol and distilled water, 
followed by a 1% Tween 80 washing, using an Amicon Ultra-Filtration Cell (Millipore Corp., 
Bedford, MA), with a 500 kDa filter membrane, under pressure (10–20 psi). 
 
F3-peptide conjugation to polyacrylamide nanoparticles 
F3-peptides were conjugated to the surface of the nanoparticles for specific targeting of the 
nucleolin receptors overexpressed on the glioma cells. The freeze-dried PAA nanoparticles (50 
mg) were dissolved in PBS (2.5 mL, pH 7.4), and bifunctional PEG (4 mg) was conjugated to the 
NP surface by amine-succinimidyl ester. This mixture was allowed to react under stirring 
conditions for 30 min, at room temperature, before undergoing thorough washings using an 
Amicon centrifugal filter (Millipore, 100 kDa), thus eliminating any unreacted ligands, and the 
final concentrated to ~20 mg/mL. Cystein tagged F3-peptide, F3-Cys peptides (0.06 µmol), were 
added to the concentrated nanoparticle solution and gently stirred overnight ( >6 hours), at room 
temperature. L-Cysteine aqueous solution was added to the mixture and stirred for 2 hours in order 
to deactivate the terminal site of the unreacted PEG. The resultant F3-targeted HPPH-conjugated 
polyacrylamide nanoparticle solution was thoroughly washed with PBS and distilled water, in an 
Amicon ultra-filtration cell (Millipore Corp., Bedford, MA), and then freeze-dried with a 5L 






Surface modification of non-targeted nanoparticles 
Dye-conjugated polyacrylamide nanoparticles (50 mg) were dissolved in PBS (2.5 mL, pH 7.4). 
Bifunctional PEG (4 mg), was added to the nanoparticles solution and then the mixture was stirred 
for 30 min, at room temperature.  A rinsing procedure was carried out using an Amicon centrifugal 
filter (Millipore, 100 kDa), removing any unreacted ligands, and concentrated to ~20 mg/mL. 
Following the addition of PEG, an aqueous solution of L-Cysteine was added to the mixture and 
stirred for 2 hours, in order to deactivate the terminal site of PEG. The resultant non-targeted 
HPPH-conjugated PAA nanoparticle solution was thoroughly washed with PBS and distilled 
water, in an Amicon ultra-filtration cell (Millipore Corp., Bedford, MA), and then freeze-dried 
with a 5L ModulyoD freeze dryer (ThermoFisher Scientific) until re-hydrated for experimental 
use.  
 







Dynamic light scattering measurements 
The size distribution of the HPPH-conjugated PAA nanoparticles in an aqueous solution was 
measured by dynamic light scattering (DLS, DelsaNano, Beckman Coulter, Inc., Brea, CA, USA). 
The surface charge of the HPPH-conjugated polyacrylamide nanoparticles in water was measured 
by zeta potential measurements, using the above instrument. 
 
Quantification of dye loading 
The amount of HPPH dye encapsulated in the nanoparticles was evaluated by absorption 
measurements using an UV-Vis spectrometer (UV-1601, Shimadzu, Scientific Instruments Inc., 
Columbia, MD, USA). The amount of photosensitizer loaded was calculated based on a calibration 
curve of free HPPH in 1% Tween-80/water, developed using the Beer-Lambert law. 
 
Reactive oxygen species detection 
Reactive oxygen species (ROS) production from the HPPH-encapsulated polyacrylamide 
nanoparticles was measured by using Anthracene-9,10-dipropionic acid disodium salt (ADPA) as 
a ROS (1O2) detection probe [48-49]. HPPH post-loaded nanoparticles were suspended in PBS and 
mixed with ADPA in a cuvette. While under constant stirring the solution was irradiated at the 
excitation wavelength to determine the ROS production rate, with the ADPA photobleaching rate 
constant, measured using fluorescence spectroscopy (FluoroMax-3, Jobin Yvon/SPEX Division, 





For cytotoxicity studies, 9L glioma cells were plated on 96-well plates, at a density of 5000 cells 
per well, and incubated at 37oC overnight. For comparison, the cells were incubated with blank 
PAA, PEGylated PAA, and F3-targeted PAA nanoparticles, at various concentrations (0.1, 0.2, 
0.5, 1.0 mg/ml), and left at 37oC, with slow intermittent rocking using a 55S single platform shaker 
(Reliable Scientific, Inc). After incubation, to remove any unbound nanoparticles, the treated cells 
were carefully washed 3 times with fresh cell medium. The cells were further prepared using the 
MTT assay kit;  25 μl of 5.0 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) in PBS was added to each well and left to incubate for 4 hours while slowly rocking. After 
4 hours the medium solution was removed and 200 μl of DMSO was added to each well, so as to 
solubilize the water-insoluble formazan crystals produced by the MTT cellular dehydrogenase 
activity in viable cells. The 96-well plate was covered with foil and left to steadily rock on a 
rocking table (Reliable Scientific, Inc) overnight. To quantify the cell viability of the treated cells, 
the absorbance spectra were analyzed, using a microplate reader (SpectraMAX Plus 384, 
Molecular Devices LLC, Sunnyvale, CA) at 550nm, and compared to untreated cells. The 




Enodotoxin levels were measured using an Endosafe-PTS (Charles River) and following the LAL 
Assay [50]. A portable endotoxin meter has sterile cartridges for detecting endotoxin in aqueous 
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samples. Within the device, a reaction between horseshoe crab blood extract, limulus amebocyte 
lysate (LAL), and bacterial endotoxin, or with a membrane component of Gram negative bacteria, 
can quantify bacterial endotoxins. All nanoparticle batches and samples were tested prior to 
injecting the nanoparticle solution into the animal model during PDT treatment.  
Based on our experience with testing endotoxin levels for the nanoparticle samples, endotoxin 
growth rates are highly sensitive to both time and temperature – longer exposure to solutions, after 
hydration, and warm temperatures can exacerbate bacteria growth. To avoid this growth and 
contamination, our nanoparticle samples are rehydrated within minimal time intervals between 
hydration and injection; in addition, the sample is refrigerated at all times post rehydration, with 




Rat 9L gliosarcoma cells (Brain Tumor Research Center, University of California, San Francisco, 
CA) were routinely maintained in Rosewell Park Memorial Institute (RSPI), with 400mg/L D-
glucose and 292 mg/ml L-gluamine supplemented with 10% fetal bovine serum, 100U/ml (3%) 
penicillin, 1mM sodium pyruvate, and 100 μg/ml streptomycin sulfate. Cells were grown at a 37oC, 
5% CO2 , 95% air and 100 % humidity environment. 
Cells were plated on the 96 well plates for the MTT assay and 35 mm culture dishes with coverslip 




In vitro set-up 
Fluence dependent PDT  
To investigate the effects of PDT phototoxicity, a series of in vitro experiments were performed 
on rat 9L gliosarcoma cells. Glass cover slips were incubated with 1 mg/mL HPPH-loaded 
polyacrylamide nanoparticles (containing F3-peptide) for 15 minutes, rinsed with appropriate cell 
media and placed in a temperature-controlled sample chamber at 37oC. Methylene blue-mediated 
cytotoxicity was then monitored, before and after illumination, by labeling the cells with 5 μL 
Calcein-AM and 10 μL propidium iodide (PI) fluorescent stains. Fluorescence observations of 
Calcein-AM (excitation: 490nm, emission: 515nm) and PI (excitation: 536nm, emission: 617nm) 
were monitored for 30 minutes, using a Perkin Elmer Ultra View Confocal microscope system 
equipped with an argon-krypton laser. Irradiating with the microscope laser, illumination was 
performed at 647 nm, with 80 μW of power, for 1 minute intervals and stopped. The live/dead 
assay allows for obvious distinctions of viable/cytotoxic cells. In living cells, intracellular esterase 
converts the non-fluorescent Calcein-AM into a green fluorescent Calcein, indicating viable cell 
metabolism. PI is barred by viable cells but can invade cells with damaged membranes. Upon 
irradiation, in a time-dependent manner, compromised cells release the green fluorescence of the 
Calcein-AM  through damaged membranes and permit the binding of PI to their nucleic acids – 
consequently emitting a red fluorescence. Upon completion of treatment, the optical lens was 
switched to a lower magnification so as to show that the treatment was localized to the illumination 
area – showing there  red stained, dead cells, which are surrounded by viable, green stained cells, 
just outside the illuminated area. 
Furthermore, fluency-dependent PDT studies were performed at illumination fluence rates of 180 
J/cm2 and 400 J/cm2. Pre-exposure images were taken using a 60X optical lens. The cells were 
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exposed for a total of 30 minutes, using a 671 nm red diode laser (model 671RLMH1W, 
Changchun Dragon Lasers Co., Ltd) with power densities of 100 mW/cm2 and 222 mW/cm2. Post-
exposure images were taken using a 20X lens, to observe the localized cellular damage. 
 
In vivo set-up 
Cranial window model 
The animal research protocol was reviewed and approved by the University Committee on Use 
and Care of Animals (UCUCA) at the University of Michigan, Ann Arbor. Biparietal 
craniectomies were performed on 8-week old Sprague-Dawley male rats (Charles River 
Laboratory, Wilmington, MA). Rats weighing between 250 to 350 g were anesthetized and placed 
into a stereotactic frame. Rat 9L gliosarcoma cells were harvested in monolayers and, following a 
full craniectomy, suspended in media, and then the cells (105) were injected, using a syringe micro-
injector (Medfusion 3500 syringe pump). The 9L cells were implanted in the forebrain, at a depth 
of 1.5 mm, through a burr hole extending 1mm below the injection location, so as to create a pocket 
for growth. To allow for serial inspection, a thin, round microscope cover slip was bonded to the 
cranial opening, with cyanoacrylate glue, creating a brain tumor window (BTW) model [51].  
 
HPPH nanoparticle administration 
Nanoparticles were synthesized and formulated according to the previously described methods. 
The nanoparticles had a dye loading dose of HPPH dye of 0.3 mg HPPH/(kg of the rat), with dye 
loading of 1% wt/(NP wt). The stock solution was determined to have nominal endotoxin levels, 
as determined by the LAL assay. Once the tumor radius reached 2-3 mm in diameter, 
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photosensitizers in the form of free dye, or dye embedded polyacrylamide nanoparticles, were 
administered intravenously through the right femoral vein, using a programmable micro-injector 
(Medfusion 3500 syringe pump). After injection, rats were kept in the dark during nanoparticle 
systemic incubation (105 minutes, 6 hours, or 10 hours) until undergoing irradiation therapy. 
 
Laser set-up 
Tumors in the BTW model were irradiated, from outside the glass window, in a cross sectional 
manner, via the exposed tumor surface immediately beneath the window. In vivo light illumination 
was performed using a 671 nm red diode laser (model 671RLMH1W, Changchun Dragon Lasers 
Co., Ltd) with tunable output power (0 – 1 W), so as to precisely expose with various fluency rates.  
The size of the laser beam was controlled with the use of a collimator (CSMA-8-B collimator, 
Newport Corp) so as to accurately control the light fluence for PDT. For all of our experiments, a 
constant beam diameter of 4 mm was used, while the distance between the cranial window and the 
collimator was fixed at 1 inch. 
Calibration of the laser was performed; the laser was tuned to the desired power, set to warm for 
30 minutes, and then checked again using a power meter to assure light fluency stability. After 
observing for a complete hour of consistent power output, the laser was cleared for PDT 
illumination. It was not typical to find fluctuations in power; and so it was important to assure 





Tumor size measurement  
Damage to sensitized tumor and brain parenchyma by photo-irradiation was observed using a Sony 
digital camera. Daily photographs of the cortical surface were taken as seen through the BTW, 
giving an evident depiction of the tumor growth patterns prior and post PDT treatments. Tumor 
growth patterns were then evaluated by delineating the tumor boundaries, based on the variations 
of pixelated coloration and measuring the total pixelated surface area of the tumor. The in vivo 
PDT efficiency was determined by tumor surface area measurements, as seen through the BTW 
model, of individual animals and animal groups. 
 
 
RESULTS AND DISCUSSION 
HPPH was loaded into nanoparticles by way of post-loading. Post-loading the photosensitizer into 
the polyacrylamide matrix of the nanoparticle causes no chemical change to the photosensitizer 
and results in a high drug loading efficiency. This loading method allows for a stable delivery of 
the hydrophobic photosensitizer under physiological conditions. The hydrogel PAA nanoparticle 
matrix protects the active form of the photosensitizer from enzymatic degradation, but allows for 
free flow of molecular oxygen, which is imperative for PDT [48, 52].  
The DLS measurements in aqueous solution showed the size of the nanoparticles to have a 
diameter of 39 ± 5 nm, with a fairly uniform size distribution. The surface charge of the F3-
modified nanoparticles was measured to be +13.2 (± 0.2) mV, whereas the non-targeted (surface 
PEGylated) nanoparticles have a charge of +1.9 (± 0.1) mV. The unmodified nanoparticles, having 
free amine groups on the nanoparticle matrix, have a surface charge of +14 (± 3). Addition of the 
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highly positive charge from the F3-peptide results in a positively charged nanoparticle, while the 
non-targeted nanoparticle has a nearly neutral surface charge due to the presence of the neutral 
PEG molecules. 
Absorption spectra of HPPH nanoparticles show a strong absorbance peak at 662 nm. Dye loading 
was measured by comparison of the 1 mg/ml nanoparticle concentration to the absorption peak 
values and the extinction coefficient of HPPH in a 1% Tween 80 solution. Florescence and 
absorbance measurements show that the post-loaded HPPH nanoparticles have a 95% loading 
efficiency, with a dye concentration of 1% by weight [32]. 
To ensure that the reactive oxygen species was generated as a response to light activating the dye 
encapsulated in the nanoparticle matrix, dye leaching needed to be examined. It is imperative to 
test dye leaching because photosensitizers outside the nanoparticle can interact with cellular 
surface proteins and organelles in vitro; furthermore, enzymatic degradation of the leached out 
HPPH dye might alter the optical properties of the dye during intraoperative in vivo applications. 
In order to survey the dye leaching, the HPPH content in the filtrate separated from the 
nanoparticles by centrifugation filtration was measured, using UV-VIS absorbance spectra.  
Dye leaching experiments of the HPPH post-loaded nanoparticle in a 1% Tween 80 water filtrate 
solution showed untraceable amounts of HPPH when testing absorbance at 665 nm [32]. This 
ensures that dye-leaching complications will be avoided during systemic in vivo circulation and 
ensures the delivery of the full pay-load of photosensitizer to cells in vitro or to tumor sites in vivo. 
These dye loading and leaching experiments confirm that the reaction between the 





Figure 3.2: Cytotoxicity test using the MTT assay. Cell viability of 9L gliosarcoma, 
evaluated after 24 hours incubation, with varying concentrations of F3-targted and non-
targeted HPPH polyacrylamide nanoparticles. Cell survival rates indicated no measurable 
differences among nanoparticle concentrations (0.1, 0.2, 0.5, and 1.0 mg/mL), including 
the cell only control group (not treated with nanoparticles). 
 
Dark toxicity of the nanoparticles was investigated by performing MTT assays, using various 
concentrations of nanoparticles. F3-targted and non-targeted nanoparticles were added to 9L 
glioma cells, with increasing concentrations, for survival assessment, as determined by the assay. 
These toxicity assays show that the HPPH polyacrylamide nanoparticles are non-toxic to cells, and 
exhibit a higher than 97% cell viability, up to the nanoparticle concentration of 1 mg/ml (Figure 
3.2). This dark toxicity test ensures that viability differences during PDT experiments will not be 































   
Figure 3.3: (A) Size distribution of polyacrylamide nanoparticles in solution as measured 
by DLS. (B) ROS production measurement of HPPH post-loaded polyacrylamide 
nanoparticles in DI water, with excitation peak for HPPH at 665nm: Linear fitted plot of 
fluorescence change of ADPA as a function of irradiation time, irradiation performed at 
378nm.  
 
The ROS production from HPPH post-loaded polyacrylamide nanoparticles was tested using 
ADPA photobleaching [48-49]. Figure 3.3 shows the fluorescence spectra of HPPH 
polyacrylamide nanoparticles with 1% wt/(NP wt) dye loading and nanoparticle concentration of 
0.068 mg/ml. The conjugated nanoparticles show very strong fluorescence at 665nm [32]. The 
ADPA oxidation rate (k-value) is calculated to be 1.4x10-4/s for post-loaded HPPH polyacrylamide 
nanoparticles. 
To confirm that cell death in response to light activating ROS, dye leaching needed to be examined. 
Performing dye leaching tests proves important because photosensitizers outside the nanoparticle 
can interact with cellular surface proteins and organelles, resulting in unwanted cytotoxicity. In 
order to assess the dye leaching, the filtrate from washing HPPH nanoparticles was separated from 
the nanoparticles by centrifugation filtration and measured using UV-Vis absorbance spectra. 
There was no detectable absorbance at 665 nm, verifying negligible dye leaching of HPPH out of 
the HPPH post-loaded polyacrylamide nanoparticles. This verifies that the detected reaction 
between the HPPH dye and the ROS must occur within the nanoparticle. It also verified that post-
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loading the HPPH dye to the nanoparticle matrix completely eliminates dye leaching, thus ensuring 
the delivery of the full pay-load of photosensitizer to cells in vitro or to tumor sites in vivo. 
 
 
Figure 3.4: Confocal images of 9L cell lines treated with F3-targeted HPPH post-loaded 
PAA nanoparticles. Intensity dependent cytotoxicity, induced by F3-targted HPPH PAA 
nanoparticles and laser irradiation at 671 nm. The 9L gliosarcoma cells were incubated 
with HPPH nanoparticles and irradiated with fluencies of 100 J/cm2 and 144 J/cm2. Images 
were taken (A) before light exposure; (B-E) over 30 min of light exposure at a dose of 100 
mW/cm2. Images were taken (F) before light exposure; (G-J) over 30 min light exposure 
at a dose of 144 mW/cm2. Cytotoxicity was monitored by labeling the cells with Calcein-
AM (green, for viable cells) and propidium iodide (red, for dead cells). Measurements 





Figure 3.5: Cell viability assessment for the phototoxic effects of F3-targeted HPPH post-
loaded polyacrylamide nanoparticles on a 9L cell line. Fluency dependent PDT efficiency 
at light doses of 100 mW/cm2 and 144 mW/cm2, over the course of 20 minutes of 
illumination.  Cells exposed to a higher fluency responded with a more rapid cellular death 
than for a lower fluency. 
  
To investigate the fluence rate dependence of PDT phototoxicity, a series of in vitro experiments 
were performed on rat 9L gliosarcoma cells. Using the protocols for the live/dead assay, 9L cells 
were irradiated at two separate light intensities, 100 mW/cm2 and 144 mW/cm2, using an excitation 
wavelength of 671 nm. A series of images of the cells were sequentially taken over 20 minutes, in 
1 minute intervals, using an Ultra-View confocal microscope (Figure 3.4).  
In order to examine the effect of irradiating the 9L cells at different laser fluencies; cells were 
exposed to two laser fluencies and the confocal images are displayed side-by-side (100 mW/cm2: 
Figure 3.4 A-E; 144 mW/cm2: Figure 2.4 F-J). In preparation for light irradiation, all cells were 
stained by Calcein-AM, showing green fluorescence, verifying cell viability for both experiments 
(Figures 3.4A, 3.4F). After 5 minutes of irradiation, the cells exposed to the greater fluence rate 
showed initial signs of cell death, by the presence of PI-stained red nuclei (Figure 3.4G) while the 
lesser fluence rate shows no sign of cellular death (Figure 3.4B). After completing 10 minutes of 
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illumination, the cells exposed to  the higher illumination fluence show a convincing display of 
cellular death (Figure 3.4H) and continuously improve in displaying cytotoxic effects with total 
cellular death 15 minutes into the experiment. The lower fluence rate displayed primary signs of 
cell death at 10 minutes and the cellular cytotoxicity increased through 15 and 20 minutes of 
illumination (Figures 3.4D, 3.4E).  
These cell viability experiments show that photosensitizers exposed to a higher fluence rate result 
in a significantly increased rate of cellular cytotoxicity. Complete cellular death was achieved in a 
shorter time frame, this was all signified by a rapid release of Calcein-AM (green) through the 
compromised cellular membrane allowing for the incorporation of PI (red) into the nucleus.  These 
results demonstrate the light- dose dependency of PDT cytotoxicity, which would enhanced the 
PDT efficieny by better understanding cell death rates as exposed to various light dose.  
 
 
Figure 3.6: (A) Photograph displaying photodynamic therapy setup. Rats with 
BTW are placed in sterotactic frames with distance between cranial window and 
laser collimator fixed at 1 inch. Photographs of a tumor as seen through the BTW 




The in vivo efficacy of HPPH mediated photodynamic therapy was evaluated by tumor growth 
experiments performed on rat bearing intracranial 9L glioma. When the brain tumor radius reached 
3 mm in diameter, the HPPH photosensitizers, in the form of free dye, or of dye loaded 
polyacrylamide nanoparticles, were administered intravenously, via the femoral vein. The HPPH 
PAA nanoparticles were administered at a dose of 60 mg/kg, which corresponds to 1% wt/(NP wt) 
dye loading. This dose has proved to be safe, in accordance with our previous nanoparticle 
optimization and toxicology studies [51, 53]. In line with previous incubation studies, 105 minutes 
after intravenous injection of HPPH, interstitial PDT treatment at 671 nm was administered, using 
a fixed light dose of 180 J/cm2 [35]. Daily photographs of the cortical surface were taken, prior 
and post PDT treatments, to quantify tumor growth patterns (Figure 3.7).  
 
 
Figure 3.7: A series of cranial window pictures of an implanted 9L glioma, before and 
after the PDT, using non-targeted HPPH polyacrylamide nanoparticles and a time interval 
of 6 hours between nanoparticle injection and light illumination. The dotted circle encloses 
the tumor area in each picture.  
 
 
Figure 6 shows images of glioma development, as seen through the brain tumor window, for 
untreated animals (withheld laser illumination and NP administration), and animals treated with 
HPPH free dye, F3-targeted HPPH polyacrylamide nanoparticles, and non-targeted PEGylated 
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HPPH polyacrylamide nanoparticles. The untreated gliomas grew continuously throughout the 
observation period. Animals treated with HPPH free dye and laser illumination show a slight 
regression in tumor surface area, accompanied by a period of necrotic tissue post-PDT treatment.  
Among the animal groups tested, those administered with HPPH post-loaded in PAA nanoparticles 
showed the most effective treatment in inducing phototoxicity, in response to PDT. Gliomas 
treated with HPPH containing nanoparticles and irradiated with laser light resulted in a significant 
decrease in tumor surface area and produced necrosis localized to the treatment regions, 
demonstrated by the opaque tissue, as seen through the brain tumor window. Tumor growth 
patterns of the F3-targted HPPH NPs and non-targeted HPPH PEGylated NPs showed analogous 





Figure 3.8: BTW view of the brain on the day of photodynamic therapy (Day 0), showing tumor 
growth of approximate size of 3mm. Days following PDT treatment, extensive necrosis was seen 
in the treatment area for those animals administered HPPH nanoparticles and irradiated with the 
laser light.  
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The differences in treatment response between HPPH administered in the form of free dye and 
post-loaded in nanoparticles can be explained to some extent by the pharmacokinetic behavior of 
these two delivery methods. The extreme hydrophobic, lipophilic photosensitizer, in the form of a 
free dye, shows a decline in activity, possibly due to drug aggregation and drug accumulation 
variations within the treatment area. This limited efficacy of the hydrophobic photosensitizer 
suggests the need for a drug delivery system for enhanced PDT efficiency. 
In contrast to the HPPH free dye treated animal group, the similar PDT efficacy and tumor 
response between active targeting (F3-targeted NPs) and passive targeting (PEGylated NPs) 
nanoparticles indicate equivalent sensitizer exposure within the localized region during the 30 
minute irradiation. As seen in vitro, complete cellular death was experienced between 15 and 20 
minutes into the treatment, with fluency rates identical to that of the in vivo studies. In vivo 
phototoxicity using active targeting is achieved through the continuous systemic circulation of 
nanoparticles, even after the nucleolin bound, F3-targeted nanoparticles have been completely 
irradiated - damaging the entirety of the exposed epithelial surface receptors. Passive targeted 
PEGylated nanoparticles accumulate in the tumor region by the EPR effect, in addition to the 
uninterrupted distribution of nanoparticles throughout the treatment area by way of systemic 
circulation. Figure 3.9 and Figure 3.10 detail tumor growth response and necrotic tissue 
development post-PDT for these delivery methods. These figures affirm that the cytotoxic 
efficiency achieved by F3-targeted nanoparticles parallel that of PEGylated nanoparticles. These 
identical PDT effects between active and passive targeting were the result of a complex interplay 
of the amount of HPPH in the treatment region and its replenishment after local photobleaching 





Figure 3.9: Tumor response as a result of delivery dependent photodynamic therapy. 
HPPH in the form of free dye and post-loaded in nanoparticles, F3-targeted or non-targeted 
polyacrylamide nanoparticles, were intravenously injected. Following nanoparticle 
incubation time of 105 minutes tumors were irradiated at 180 J/cm2 using 671 nm laser 
light through the BTW and observed daily. 
 
 
Figure 3.10: Tumor necrosis measurements. Following nanoparticle incubation time of 
105 minutes tumors were irradiated at 180 J/cm2, for 30 minutes, using 671 nm laser light. 
Measurements were taken for animal groups treated with non-targeted HPPH PEGylated 
polyacrylamide nanoparticles and F3-targted HPPH polyacrylamide nanoparticles. Both 
treatment groups demonstrate irradiation induced tumor necrosis. 
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Figure 3.11 shows the tumor growth patterns post-PDT as a result of varying incubation times, the 
time between nanoparticle administration and laser illumination. Irradiation of the tumor site were 
performed 105 minutes, 6 hours, and 10 hours following the administration of HPPH PEGylated 
nanoparticles. The animal group receiving PDT treatment 10 hours post-injection of HPPH 
nanoparticles experienced a retarded tumor growth post-treatment through day four followed by 
an aggressive development of tumor growth and nominal necrotic tissue. PDT treatment following 
6 hours incubation of the HPPH nanoparticles resulted in complete eradication of the tumor, 
indicated by the appearance of opaque necrotic tumor as seen through the BTW model (Figure 3.8 
and 3.12). Tumor regrowth patterns for this animal group display equivalent/similar tumor area 
measurements eight days post-treatment as seen on treatment day (Figure 3.11 and 3.12). Laser 
irradiation performed 6 hours after injection displayed maximal tumor regression and necrotic 
tissue development over other treatment groups. Animals incubated with HPPH nanoparticles for 
105 minutes experienced similar effects from treatment with the exception of distinct tumor re-
growth patterns following the eight day of observation. This suggests HPPH PEGylated 
nanoparticle retention and circulation provided greatest photosensitizer exposure in the treatment 





Figure 3.11: Tumor response for variations in incubation times of non-targeted HPPH 
PEGylated polyacrylamide nanoparticles. Following nanoparticle incubation time of 105 
minutes, , 6 hours, and 10 hours tumors were irradiated at 180 J/cm2 using 671 nm laser 
light through the BTW and observed daily.  
 
 
Figure 3.12: Tumor necrosis measurements for variations in incubation times of non-
targeted HPPH PEGylated polyacrylamide nanoparticles. Following nanoparticle 
incubation time of 105 minutes, 6 hours, and 10 hours tumors were irradiated at 180 J/cm2 
using 671 nm laser light. Prolonged duration of tumor necrosis found in treatment groups 
receiving irradiation following 6 hour incubation.  
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Response of glioma treated with HPPH post-loaded PEGylated polyacrylamide sensitized at 671 
nm, using varying irradiation regimens: power density of 100 mW/cm2 at incident fluence of 180 
J/cm2, power density of 100 mW/cm2 at incident fluence of 260 J/cm2, power density of 144 
mW/cm2 at incident fluence of 260 J/cm2 (Figure 3.11 and 3.12).  Comparing two conditionally 
different animal groups that have been exposed to the same fluence rates will demonstrate clear 
relationships between incident irradiation fluence rate and therapeutic outcome. This approach 
investigates the effective delivery of higher light intensities with minimal prolongation of 
treatment time (144 mW/cm2, 30 minute exposure time) and lower light intensities with a broader 
range of treatment times (100 mW/cm2, 45 minute exposure time). 
 
 
Figure 3.13: Representation of animal groups receiving PEGylated HPPH polyacrylamide 
nanoparticles with systemic incubation time of 6 hours between nanoparticle 
administration and laser illumination. Photographs depict the brain as seen through the 
BTW on the day of photodynamic therapy (Day 0), showing tumor growth of approximate 
size of 3 mm, and the days post-treatment. Days following PDT treatment, significant 
necrosis was seen in the treatment area for all animal groups following PDT treatment. 
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All of the fluency treatment procedures produced delays in tumor surface area growth as seen 
through the BTW model (Figure 3.13). Comparison between the various fluency treatment groups 
revealed that glioma response to power density of 100 mW/cm2 at an incident fluence of 260 J/cm2 
treatment was more desirable out of the three treatment protocols. Tumor regrowth following 100 
mW/cm2 (260 J/cm2) irradiation was delayed significantly longer than it was for treatment groups 
exposed to a power density of 144 mW/cm2 (260 J/cm2). For the animal group receiving a larger 
power density and higher fluency rate, the tumor doubling time was extended to 10 days, with 
tumor necrosis remaining at 70% of the original tumor area (Figure 3.14 and 3.15). While regrowth 
following 100 mW/cm2 (260 J/cm2) irradiation took 10 days to return to the original tumor size 
pre-treatment and tumor necrosis was at 83% of the size of the original tumor area. The discovery 
that using an increased fluency rate over longer period of illumination results in more effective 
PDT treatments proves consistent with previously reported results observed using photofrin [54-
56]. These improved outcomes could be attributed to the improved restoration of tissue 





Figure 3.14: Response of glioma treated with HPPH post-loaded PEGylated 
polyacrylamide sensitized at 671 nm using varying irradiation regimens. Following 
nanoparticle incubation time of 6 hours tumors were irradiated at 180 J/cm2 (100 
mW/cm2) – 30 minute illumination, 260 J/cm2 (100 W/cm2) – 45 minute 
illumination, and 260 J/cm2 (144 mW/cm2) – 30 minute illumination. 
 
 
Figure 3.15: Tumor necrosis measurements for variations in fluence rates of 
exposed non-targeted HPPH PEGylated polyacrylamide nanoparticles. Following 
nanoparticle incubation time of 6 hours tumors were irradiated at 180 J/cm2 (100 
mW/cm2) – 30 minute illumination, 260 J/cm2 (100 W/cm2) – 45 minute 
illumination, and 260 J/cm2 (144 mW/cm2) – 30 minute illumination using 671 nm 




Figure 3.16: Gross specimen from animal model, excised 10 days post-PDT 
therapy. Representation of brain tumor for animal groups (A,B) without 
photosensitizer or laser illumination, and (C,D) animals receiving non-targeted 
HPPH nanoparticles (6 hour incubation time) with irradiation fluence dose of 260 
J/cm2 (144 mW/cm2) using a 671 nm laser. 
 
Optical penetration depth is the tissue thickness which results in the radiant power of light to 
decreases to 1/e or 37% of its initial value [60]. Beyond this depth, tissue is exposed to laser light 
of a lower intensity, which still may be adequate for PDT. HPPH dye has a long absorption 
wavelength (λmax = 665 nm) allowing for deep penetration depth of laser light in live tissues, 
however the penetration depth varies depending on the optical properties of the treated tissue. It 
has been measured that laser light at 631nm can achieve a penetration depth of 1.5 ± 0.43mm in 
brain tissue and 2.9 ± 1.5mm in brain tumor tissue [61]. The rat models used in these experiments 
have tumors implanted into the cortex – a depth which may surpass the penetration depth 
achievable by our 671 nm laser. This limitation resulted in incomplete eradication of the base of 
the tumor, resulting in detectable growth patterns days after treatment. The utility of PDT in this 
application is restricted mainly due to the large size of the implanted tumor as compared to the 
post-surgical size of the residual tumor. However, the depth of the microscopic residual tumor 
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tissue post-surgical debulking is at a depth within treatment range, allowing PDT to be an effective 
post-surgery adjuvant therapy. 
 
CONCLUSIONS 
In vivo photodynamic therapy experiments led to more clearly defined treatments conditions for 
intra-operative glioma photodynamic therapy. We have successfully demonstrated the progress 
towards more optimal treatment conditions for glioma intra-operative PDT using HPPH 
nanoparticles. The hydrophobic photosensitizer HPPH was post-loaded into hydrogel 
nanoparticles with an average size of 39 nm, containing approximately 1% dye by weight. 
Advancements and considerable attention to nanoparticle characteristics, incubation time, and 
photosensitizer delivery are allowing for the quantification of PDT efficacy. The F3-targeted and 
PEGylated nanoparticles displayed homing and passive targeting efficiency towards the implanted 
9L glioma. Both delivery methods displayed similar capacities of delivering the photosensitizer 
within the irradiation field which was evident through the phototoxic effect, killing the tumor cells 
– resulting in necrotic tissue, and ultimately retarding tumor growth in the treatment area of the 
BTW model. PDT treatments with HPPH polyacrylamide nanoparticles, F3-targeted or 
PEGylated, produced significant arrest of tumor growth over control groups, which demonstrates 
the potential advantages of nanoparticle-based PDT agents for the intra-operative eradication of 
residual brain tumors. 
While all of these irradiation protocols produced delays in tumor regrowth and expressed 
significant amounts of tumor necrosis, investigating incident irradiation fluence rate is imperative 
in optimizing in vivo therapeutic outcomes. Photodynamic dose derives from photosensitizer 
exposure to photons and not simply by the total optical energy density irradiating a tissue sample. 
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Meaning that phototoxic success rests on the interplay of the light dose and the amount of 
photosensitizer circulating within the treatment field. Although this study was not designed to 
observe the pharmacological properties of our HPPH nanoparticles, determining photosensitizer 
concentrations in serum, tumor, and brain parenchyma within the treatment region, over the 
irradiation time, would be useful in gauging photosensitizer exposure and efficiency. This would 
quantify serum and tissue kinetics and the half-life of HPPH polyacrylamide over the therapeutic 
window.  Exploring the chemical properties of the therapeutic window during treatment and the 
hours following treatment could quantify immediate PDT outcomes and give insight for the 
therapeutic index required for tumor regression. Chemical sensors detecting relative traces of O2 
along with the resulting ROS within the tumor tissue and exposed vasculature would indicate 
optimal fluency rates and the extent to which ROS generation is necessary to create sufficient 
cytotoxic effects on the localize treatment region. This knowledge could facilitate the effective 
delivery light doses with minimal prolongation of treatment time and laser exposure. 
 
(This chapter was written with the intent of future publication) 
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Efficacy of Reactive Oxygen Species Production for 
Methylene Blue and Coomassie Blue Mixture: 
For Possible Combined Tumor Delineation and Therapy 
 
INTRODUCTION 
For most patients diagnosed with brain tumors, surgical resectioning is an essential treatment 
modality. However, visually determining tumor margins at the microscopic level when performing 
the operation proves difficult for surgeons. Measureable differences in quality of life and survival 
rates have been directly correlated to the extent of surgical resectioning, which in turn is limited 
by the ability to distinguish tumor boundaries [1-2]. In the current clinical setting, resectioning of 
the tumor is mostly aided by preoperative imaging acquired by ultrasound, X-Ray CT, or 
intraoperative MRI (magnetic resonance imaging). Tumor structural shifts and interval growth, 
not detected by preoperative image guided surgery, can lead to significant resectioning inaccuracy, 
because tumor margins detected by low resolution imaging cannot be easily translated to tumor 
margins in the operative field. Intra-operative real time imaging aided by MRI would allow for the 
surgeon to detect residual tumor tissue in the operating room. However, operative delays for 
comparative imaging, limited signal distinctions between tumor resectioning and retraction injury, 




Various attempts to visually delineate tumor margins on the operative field have been made using 
fluorescent and visible reagents: Coomassie Blue, Bromophenol Blue, fluorescein, Indocyanine 
Green, 5-aminolevulinic acid (5-ALA), and fluorescent porphyrins [3-11]. Fenestrations in the 
vasculature wall of the blood brain barrier allow these dyes to preferentially accumulate and stain 
malignant glioma for delineation of neoplastic tissue within the operative field. However, the use 
of delineating dyes has various restrictions. For instance, fluorescence based dye delineation 
requires the use of special lighting conditions under dark operative settings, posing higher surgical 
risks. Attempting adequate visual delineation between tumor and non-neoplastic tissue, required 
the use of high concentrations of intravenous contrast dyes – which can be associated with systemic 
toxicity [5]. As a result of this drawback, it is important to maintain low therapeutic doses of 
contrast dyes while sustaining delineation potential, a fiat that has proven difficult. 
The Kopelman group has investigated Coomassie Blue dye and nanoparticle delineated glioma, 
proving that this method is effective in enhancing visualization of the tumor brain interface in rat 
models while maintaining optimal operative conditions [3, 12-13]. The deep blue color of 
Coomassie Blue offers brilliant contrasts against non-neoplastic tissue, blood, and other crucial 
structures near the tumor.  
The Coomassie Blue dye has been covalently linked to the polyacrylamide matrix of a nanoparticle 
with surface modifications by conjugation of F3-peptides, for active tumor targeting, and 
polyethylene glycol (PEG), for longer plasma circulation (~24 hrs) [14]. Selective targeting and 
retention within the tumor tissue is a limiting factor for the use of free dye molecules as a 
delineating agent, which may be overcome by utilizing nanoparticles. Additional accumulation of 
the nanoparticles within tumor tissue and vasculature is abetted by the “enhanced permeability and 
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retention effect” (EPR), allowing tissue retention of macromolecules by way of leaky 
microvasculature and poor lymphatic drainage [15-17].  
Though surgery is the most effective treatments for patients with glioblastoma, residual tumor cells 
left behind during surgical resectioning could cultivate recurring tumors. Adjuvant therapy such 
as photodynamic therapy could aid in the removal of residual tissue left behind by surgeons, 
enhancing the chances of palliating the disease and increase patient survival rates. 
The Methylene Blue dye has been reported for numerous medical applications and therapies 
including photodynamic therapy [18-22]. Similar to delineation dyes, Methylene Blue has the 
potential to accumulate in tumor tissue, however enzymatic degradation of the dye produces a 
colorless form of the dye - failing to pigment tumor tissue [23]. Its incorporation into a nanoparticle 
composed of polyacrylamide (PAA) matrix serves to embed the active form of the Methylene Blue 
photosensitizer, protecting it against enzymatic degradation into the colorless and photochemically 
inactive form of Leuko-Methylene Blue (LMB). Thus, incorporating the photosensitizing dye into 
the same polyacrylamide nanoparticle designed for delineating dyes, might serve to guard the 
active form of Methylene Blue [23]. 
It has previously been shown, that polyacrylamide nanoparticles can be utilized as a vehicle to 
transport for multiple types of molecules such as delineating/imaging agents and drugs to tumors 
[24-31]. Thus, collectively incorporating Coomassie Blue and Methylene Blue dyes in 
polyacrylamide nanoparticles can potentially produce a biofunctional agent that can be used for 
both delineation purposes during intraoperative surgery and as a photosensitizing drug in the 
adjuvant treatment of PDT. 
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Here we investigate the possibility of combining Methylene Blue and Coomassie Blue for potential 
dual application of diagnostics and therapy and quantify its ability to efficiently produce reactive 
oxygen species. A mixture of Methylene Blue and Coomassie Blue dye, at different ratios, was 
used and the amount of reactive oxygen species produced 'k-value' was monitored as a function of 
this ratio. We observe a steady decrease in the k-value with increasing concentration of Coomassie 
Blue dye. This may be attributed to the quenching of the ROS due to incorporation of Coomassie 
Blue dye into the Methylene Blue mixture. These results suggests that introducing Coomassie Blue 
and Methylene Blue dye in the nanoparticle will reduce the PDT efficiency and ultimately might 




Methylene Blue succinimidyl ester (MB-SE) was purchased from Emp. Biotech.  Phosphate-
buffered solution (PBS) was made using a phosphate-buffered saline tablet from Sigma-Aldrich. 
9,10-dipropionic acid disodium salt (ADPA) was purchased from Invitrogen. A stock solution of 
100 µM ADPA was made in water and kept in the dark until use. The water used throughout the 
experiments was purified by Millipore Milli-Q Advantage A10 water purification system by 






Reactive oxygen species detection 
ADPA was used to detect the rate of production of ROS from Meythelene Blue when combined 
with Coomassie Blue dye, compared to Methylene Blue free dye. ADPA is an anthracene based 
dye which becomes oxidized by ROS, producing non-fluorescent ADPA endoperoxide, leading to 
a reduction in detectable fluorescence intensity [32]. A stock solution of ADPA in PBS (100 µM) 
was prepared and stored in the refrigerator, under dark conditions (wrapped in foil covering), 
between uses. However, fresh solutions of ADPA were prepared for every experiment to avoid 
inaccuracies as a result of oxidation/photobleaching during storage. Solutions of 80 µL ADPA was 
mixed into 2 mL of 1 µM Methylene Blue free dye in PBS solution. Coomassie Blue dye was 
added to the 2 mL solution at varying concentrations (1, 2, 2.5, 3, 3.5, 5, 8, 10 µM). The oxidation 
of the ADPA, due to the ROS produced, was monitored by measuring the fluorescence intensity 
for 25 minutes (measuring time points of 0 sec, 1 min, 2 min, 3 min, 4 min, 5 min, 10 min, 15 min, 
20 min, and 25 min), while the solution was irradiated using 660 nm excitation beam (slit width 
of 10 nm) under constant stirring to ensure solution homogeneity and to replenish oxygen diffusion 
within the sample. The fluorescence spectrum of ADPA was evaluated and measured using a 
fluorimeter (FluoroMax-3, Jobin Yvon/SPEX Division, Instruments S.A. Inc., Edison, NJ, USA).  
 
RESULTS AND DISCUSSION 
The production of reactive oxygen species from Methylene Blue free dye was tested by monitoring 
the fluorescence emission from ADPA. Figure 4.2A shows the fluorescence emission spectra of 
ADPA in a mixture of 1.0 µM Methylene Blue dye in PBS, after irradiation at the excitation 
wavelength at different time points. The spectra shows a gradual decrease in the fluorescence 
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emission intensity of ADPA with the increase in irradiation time. The slope of the linear curve 
obtained by plotting the logarithm of the ratio of ADPA fluorescence intensity at 431 nm, at time 
't' vs the initial intensity, provides the rate constant, as shown in Figure 4.2A. ADPA in a mixture 
of 1.0 µM Methylene Blue dye in PBS expresses a very strong fluorescence at 431 nm, with first-
order decay rate constant (k-value), calculated as ln([ADPA]t/[ADPA]o) = -kt, to be 5.5x10
-4/s 
[32]. 
Mixtures of Methylene Blue and Coomassie Blue dye, at different ratios, were used to determine 
the effectiveness of ROS production from each mixture and obtain an optimal ratio. This optimized 
ratio can then be used for preparation of the dual-functional nanoparticles. The sensitivity of 
Methylene Blue ROS generation was tested to evaluate the effect of co-loading a delineating dye, 
Coomassie Blue, along with the photosensitizing dye Methylene Blue into polyacrylamide 
nanoparticles.  
 




Figure 4.2:   ADPA was used to detect the ROS production from Methylene Blue 
when combined with Coomassie Blue dye. The logarithm of the ratio of ADPA 
fluorescence intensity at 431nm provides the first order decay rate constant, or k-
value. A) Calculation of the rate of ROS production from MB free dye using 





Solutions of various concentrations of Methylene Blue to Coomassie Blue were examined under 
identical conditions of irradiation, using 1.0 µM MB free dye in PBS, with 660 nm excitation for 
25 minutes. The decay rates of ADPA fluorescence, for each Methylene Blue – Coomassie Blue 
concentration ratio, were examined using fluorescence spectroscopy and plotted in Figure 4.3 so 
as to compare the ROS production rates using increased amounts of Coomassie Blue delineation 
dye. Methylene Blue dye solution or Methylene Blue - Coomassie Blue mixture solution of various 
concentrations in PBS was mixed with ROS detecting probe, ADPA, in a cuvette.  
 
 
Figure 4.3: Comparison of ROS generation from the various compositions of 
Methylene Blue and Coomassie Blue mixtures.  
 
Methylene Blue free dye exhibited a significantly faster fluorescence decay compared to 
Methylene Blue – Coomassie Blue mixtures, clearly indicating Methylene Blue dye alone has 
better ROS production ability. Among all formulations, the lowest concentration Coomassie Blue 
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mixture showed the highest reactive oxygen production. ROS production from 1:2 Methylene Blue 
and Coomassie Blue was reduced by 25%, compared to Methylene Blue alone, due to the presence 
of Coomassie Blue.  
After a sudden decrease, the k-value begins to plateau for the dye ratios between 1:2.5 and 1:8 
Methylene Blue to Coomassie Blue (Figure 4.3). This range showed equivalent intensities, with 
k-value of about 3x10-4, approximately a 50% reduction in ROS production as compared to 
Methylene Blue dye solution. The ROS generation of various dye compositions was significantly 
less than that of Methylene Blue dye only, and continued to decrease as the Coomassie Blue 
content in the solution increased.  
ROS production, in the form of singlet oxygen, superoxide, peroxides, etc., is generated from the 
excited Methylene Blue molecule, with the nature of the mix depending on the ratio of monomeric 
to dimeric state [33]. The primary component of the generated ROS, singlet oxygen, has a short 
lifetime (0.04 µs) and an average diffusion distance of 0.02 µm in media [27]. This limitation gets 
worse with a highly concentrated media sample, and also when increasing the amount of 
Coomassie Blue molecules in the sample, because the proximity of excited photosensitizer to other 
quencher/dye molecules could result in significant quenching of the radicals produced. As 
displayed in Figure 1, using Coomassie Blue dye contents greater than 2.5 µM, the k-values are 
observed to plateau, or in some cases decrease, with the increased addition of Coomassie Blue dye. 
This can be attributed to saturation and the quenching of ROS production. Additionally the 
presence of Coomassie Blue dye can lead to dimerization or aggregation of the Methylene Blue 
dye, which has lower quantum yield, or even formation of complexes between the two, which 
could potentially quench the Methylene Blue dye. All or some of the above mentioned factors 
leads to a reduction in ROS production.  
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Irradiation of brain tumors, for PDT, in Chapter 2 utilized Methylene Blue polyacrylamide 
nanoparticles with 0.37% wt/(NP wt) dye loading. In comparison, the Coomassie Blue 
polyacrylamide nanoparticle used for tumor differentiation studies required 7% wt/(NP wt) 
Coomassie Blue dye loading for obtaining a sufficient color delineation effects in a rat BTW model 
[13]. Among all preparations, only the Methylene Blue and Coomassie Blue in 1:8 and 1:10 ratio 
would allow for a Coomassie Blue dose effective for delineation, however with ROS production 
efficiency of 51% and 37%, such mixtures fail to generate effective cytotoxic destruction capable 
to elicit a long-term damage to the tissue.  
While dye loading contrast agents at such high doses allows for visual differentiation of tumor 
tissue from adjacent brain tissue, consequently the high dye loading reduces the PDT efficacy due 
to decrease in ROS production. Meanwhile, dye loading contrast agents in low concentrations 
would permit sufficient ROS production, insignificant amounts of delineating dye would result in 
undetected demarcation between healthy and tumor tissue for in vivo delineation purposes.   
 
CONCLUSIONS 
Here we investigate the combination Methylene Blue and Coomassie Blue dyes for potential dual 
application of diagnostics and therapy and quantify its ability to efficiently produce reactive 
oxygen species. A mixture of Methylene Blue and Coomassie Blue dye, at different ratios, was 
used and the amount of ROS produced 'k-value' was monitored as a function of this ratio. We 
observe a decrease in the k-value with increasing concentration of Coomassie Blue dye, e.g., a 
50% reduction in ROS production at 1:2.5 and only 37% efficacy at 1:10 Methylene 
Blue:Coomassie Blue, as compared to a pure Methylene Blue solution . This is attributed to the 
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quenching of ROS due to the incorporation of Coomassie Blue dye into the Methylene Blue 
mixture. These results suggests that introducing Coomassie Blue in addition to Methylene Blue 
dye in the nanoparticle will reduce the PDT efficiency and ultimately might not be optimal for this 
dual application.  
The results of combining PDT and visual delineation emphasizes the need for an alternate strategy 
to achieve the goal of tumor delineation and therapy. Therefore, it is necessary to investigate the 
relationship between two separate nanoparticles, one for delineation purposes and the second 
dedicated for therapeutic treatment. Systemic interplay and accumulation in the treatment field 
would need to be investigated to ensure concentrations of both the delineating nanoparticle and 
photosensitive nanoparticle to serve their individual purpose. 
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1. Nanoparticles for therapy and tumor delineation: This thesis focuses on development of 
nanoparticles as a PDT agent and their application to glioma as an adjuvant therapy to surgery. 
Thus, as mentioned in chapter 4, using the same nanoparticle for therapy as well as for delineating 
the tumor boundary is an attractive proposition. However there lies a delicate balance between the 
ratio of photosensitizer and the contrast agent that can be incorporated into the nanoparticle.  A 
high loading of contrast agents would be needed to provide a clear visual demarcation, however 
this in turn would reduce the efficacy of PDT by quenching the amount of ROS produced. 
Additionally some photosensitizers, such as Methylene Blue, have a drawback that at high local 
concentration they tend to form molecular dimers, which reduces the ROS production efficiency. 
A few alternate approaches that might enable this dual mode are listed below: 
(i). Utilizing Indocyanine Green (ICG) as a multifunctional molecule for therapy and providing 
visual contrast agent: ICG is a tri-carbocyanine dye that has been approved by the FDA for several 
applications [1]. Although it has a relatively low yield of ROS production, as compared to 
Methylene Blue or HPPH, it has been successfully utilized for treatment of tumors in the past [2-
4]. The photo-toxicity of the ICG comes from two mechanisms: 1) the production of ROS that 
results in PDT, 2) Localized heating which is known as photothermal therapy [2-4]. Additionally, 
ICG can be used as visual contrast as well as a fluorescent contrast agent. The deep green color 
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can provide a strong visual contrast, and has been previously used to demarcate rat glioma with a 
high degree of success [5]. ICG also has excellent fluorescence properties that have been exploited 
for imaging tumors [6]. The main advantage of using ICG over other commonly used 
photosensitizers is that its absorption peak (780 nm), as well as its fluorescence emission peak 
(~800 nm) lies in the infrared region of the spectrum, making it extremely efficient for in vivo 
applications due to the larger penetration depth of light at this wavelength, compared to the visible 
region. With ICG nanoparticles it may be possible to achieve this aim of using the same 
nanoparticle as contrast agent as well as for therapeutic applications. Incorporating ICG into a 
nanoparticle will also improve other undesirable properties seen in other photosensitive dyes, such 
as 1) tendency to dimerize, 2) fast photobleaching, 3) molecular degradation as well as cell specific 
targeting abilities [7]. The challenge lies in designing the appropriate nanoparticle as the carrier 
for ICG and optimizing its loading.   
(ii). Utilizing core shell nanoparticles containing photosensitizers and noble metals: Using a noble 
metal core it is possible to enhance the efficiency of the photosensitizer to produce ROS [8-9]. 
This enhancement is due to the presence of surface plasmon resonance, which is the act of 
oscillating electrons present on the surface of noble metals by the activation of light. Surface 
plasmons can be excited by illuminating the metal surface at an appropriate wavelength [10]. By 
maintaining the photosensitizers at appropriate distance from the metal surface, typically on the 
order of 10 nm, it is possible to enhance the dye’s characteristics - fluorescence and generation of 
ROS. Other properties such as resonance energy transfer and surface non-linearity can also provide 
the desirable effects [11]. Light illumination in the presence of the metal core will not only irradiate 
the cells, but also significantly heat the adjacent tissue and thus contribute towards cellular death 
due to photothermal effects. This will lead to a synergistic effect, thereby improving the cell killing 
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efficiency of the nanoparticle. Additionally, the scattering from metal surface may also enhance 
the visual contrast provided by the photosensitizer. These nanoparticles containing a metal core 
also have the potential to lend excellent contrast enhancements for imaging modalities such as X-
Ray CT and photoacoustics, which are popular diagnostic tools. 
   
2. Dynamic monitoring of oxygen levels in tissue before, during, and after therapy: Oxygen 
plays a key role in PDT. The photosensitizers, when irradiated with an appropriate wavelength of 
light, becomes excited and this energy is transferred to oxygen, so as to create ROS [12]. Thus 
monitoring the tissue oxygen level before treatment can be extremely critical, to predict and 
evaluate the success of this therapy. Additionally, continuous monitoring of oxygen levels during 
light irradiation will enable a better fundamental understanding of the dynamics of this process in 
vivo (oxygen consumption and replenishment at different tissue depth). Several different types of 
nanosensors have been utilized in the Kopelman lab for quantitative measurement of molecular 
oxygen in cells and in vivo using fluorescence and photoacoustics [13-14]. These nanosensors can 
be used along with the photosensitizer loaded nanoparticle for monitoring the oxygen level in 
tumors. By having the same polymer matrix as well as physical and chemical properties, the 
nanoparticle mixture is expected to have a similar distribution throughout the tumor after injection 
into the animals. Alternately, the photosensitizer itself can be used as a reporter of the local oxygen 
level in addition to therapeutic use [15-16].     
           
3. Monitoring the dynamics of therapy and determining the therapeutic index: Clinically PDT 
has been performed using the photosensitizer in its free molecular form. The use of nanoparticles 
for this application has recently gained prominence, and to maximize the effect of nanoparticle 
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aided PDT, it is essential to study the dynamics of cell killing and changes in tissue properties 
during the therapeutic window, as well as monitor the local nanoparticle distribution. This 
necessitates the quantification of nanoparticles inside the tumor tissue, right before and during the 
light irradiation process. Dynamic quantification of the three dimensional concentration of the 
nanoparticle in animal models can be achieved using imaging techniques, such as MRI, X-Ray, 
optical imaging, etc., and by loading an appropriate contrast agent into the nanoparticle [17]. The 
damage to tumor tissue, and the effective cellular death, at different depths, can be monitored by 
staining the cells with different markers (e.g., propidium iodide) and performing in vivo optical 
microscopy [18].  Staining the different cellular components will enable us to monitor the 
dynamics of tissue damage at the subcellular level. Alternately, assessment of this information can 
be achieved using histopathology, although this would require sacrificing a large number of 
animals to obtain temporal information. 
Another important parameter is the determination of the therapeutic index of this type of 
nanoparticle. This is an essential factor that would give an indication regarding the suitability of 
these nanoparticles as drugs and possible applications on humans.  
 
4. Investigating adverse effects and treatment response: Our study demonstrated tumor growth 
response to the use of nanoparticle mediated photodynamic therapy, however patient pain 
assessment and visual impairments have not been examined for these treatment parameters. The 
side effects may be mild, moderate, or severe but these are not yet known. While treating the 
animals with various treatment regimens, no adverse effects of the treatment were apparent.  
(i). Abating treatment induced pain in patients: Light illumination and fluency rates are key factors 
in refining neoplastic response to therapy. Although various illumination protocols may allow for 
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the eradication of residual cells, the therapy protocol may induce intolerable discomfort for 
patients. Animals were stabilized in stereotactic head holders and anesthetized with inhaled 
isoflurane during irradiation. These conditions made it difficult to assess pain tolerance during 
therapy sessions as a result of warmth generated during irradiation treatments. Pain can be 
controlled by cooling off the tumor site location, however this method would have extended 
investigations associated with vasodilation versus vasoconstriction and variations in nanoparticle 
delivery to the tumor site. This retrospective analysis between irradiance and pain could assist in 
fixing maximal power doses and fluency rates.  
(ii). Assessing laser effects on visual performance: In addition to pain evaluation, routine eye 
examinations pre- and post-therapy are necessary for detecting retinal damage. Long periods of 
laser exposure to the brain may cause histological changes to the eye [19-20]. Systemic circulation 
of photosensitizers inherently passes through the choroid, vascular layer located between the sclera 
and retinal walls, and, if irradiated, iatrogenic phototoxicity to nerve cells in the retina and macula 
would occur. The macula covers about five degrees of the visual field, however it is the only part 
of the eye that enables precise vision and detection of colors. If extensive damage occurs in the 
retinal periphery, impairments to normal vision may cause nearsightedness [21]. Furthermore, 
disruptions of membrane pumps responsible for regulating hydration of the eye can result in 
pressure changes within the eye causing temporary visual disturbances. These potential hazardous 
destructions of the eye could limit patients from resuming normal activity or function as a result 
of thermal and scattering effects of lasers [22]. Optimal PDT condition that involve pain reduction 
and treatment efficiency with better defined properties within the therapeutic index to decrease 




5. Combination of surgery and PDT: The primary focus of this thesis is utilizing nanoparticle 
containing photosensitizers for PDT, as an adjuvant therapy to surgery. The results presented here 
show that the nanoparticles efficiently halt the tumor growth and a large amount of necrosis is 
observed on the tumor surface. However the halting of the tumor growth is temporary, indicating 
that the effectiveness of this therapy is mostly superficial. Monitoring the tissue damage as a 
function of depth, by performing experiments proposed in the previous section, will help in 
optimizing this specific therapeutic process. Additionally, the efficacy of this process can be 
improved by optimizing the light dose and the different associated parameters, such as the photon 
flux, illumination process, etc. Modeling the light propagation through the brain/tumor tissue 
containing nanoparticles will give an insight into the intensity of light at different depths. This can 
be achieved by using different simulation techniques, with the Monte Carlo approach being the 
most commonly used method [23]. Most simulations are performed on tissue matrix, however the 
addition of nanoparticles, which have excellent scattering properties, may cause significant 
deviations from a tissue only matrix and affect the depth of light penetration.  
The actual effectiveness of this proposed approach can truly be evaluated by first performing 
surgery followed by PDT. Surgically removing the brain tumor will eliminate the bulk of the tissue, 
leaving behind minute traces of tumor residue that, based on the current results presented here, 
could be successfully eradicated using PDT.   
 
6. Considering the biological and molecular responses to PDT: Destruction to the vascular 
network surrounding the treated tumor tissue, either angiogenic or healthy, after the completion of 
PDT treatment greatly affects the degree of tumor curability. 
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Vessel constriction and leaky vasculature endothelium can result in post-PDT tumor hypoxia, 
inhibiting possible tumor regeneration [24-25]. Monitoring these vasculature responses to PDT 
treatment can be achieved using imaging techniques such as intrinsic fluorescence or 
photoacoustic imaging. The endothelial and microvasculature damage in response to PDT can be 
monitored using fluorescent microscopic imaging in live animals, pre- and post-treatment, without 
destroying the imaged cells and tissue. Similarly, employing photoacoustic imaging of blood, we 
can monitor destruction of microvasculature, resulting in leaky vasculature, and vascular repair 
following therapy. Blood has a light optical absorption peak of 532 nm, generating a strong 
photoacoustic signal making it an advantageous method for monitoring the effects of PDT on 
vasculature surrounding the tumor [26].  
Ensuring maximal destruction of angiogenic vasculature post-PDT may enhance the long-term 
tumor control. Endothelium-derived nitric oxide (NO) has vasodilatory properties and is a 
mediator of angiogenesis, and when stimulated by vascular endothelium growth factor (VEGF) it 
upregulates the expression of nitric oxide synthase (NOS) [27-28]. Designing our nanoparticle to 
incorporate agents inhibiting nitric oxide synthase or scavenging nitric oxide could assist with 
tumor regression patterns post-therapy.  The release of such drugs within the treatment location 
and reducing the NO bioactivity would allow for vasoconstriction and attenuate angiogenesis.  
Photodynamic therapy of tumors results in the rapid induction of inflammatory response that is 
crucial for the suppression of tumor growth post-treatment. This response is activated by signal 
transduction pathways that lead to the infiltration of leukocytes, predominately neutrophils, into 
the treatment area [29]. After infiltration, neutrophils undergo apoptosis followed by macrophages, 
and other phagocytes, consuming the apoptotic neutrophils – resolving the inflammatory response. 
Regulating the activation of neutrophils, macrophages enhance the clearance of treated tissue and 
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activate antitumor immunity. To ensure the patient’s inflammatory response is not prolonged, we 
can utilize the idea of incorporating NO inhibitors in the treatment region. It has been discovered 
that the production of small amounts of NO can enhance the recruitment of neutrophils [29].  This, 
along with a potential decrease in angiogenesis, can possibly leading to a condensed inflammatory 
response and a suppression of tumor regrowth. Therefore measuring and regulating the NO levels 
within the treatment region may facilitate the understanding of the effects of NO levels post in vivo 
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